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GENERAL INTRODUCTION 
Respiratory disease in cattle typically occurs shortly after calves 
have been weaned, transported, and placed in a feedlot (this is referred 
to as shipping fever) (Jensen, 1976). The clinical signs, lesions, and 
death loss in shipping fever usually can be attributed to bacterial 
pneumonia due to colonization of the lung by resident flora, Pasteurella 
hemolytica, Pasteurella multocida, or Hemophilus somnus. The causative 
factors are believed to include; 1. stress-induced release of 
glucocorticoids leading to immunosuppression and 2. mycoplasma and/or 
viruses which cause a transient infection and often decrease the lung's 
resistance to bacterial infections (e.g.. Infectious Bovine 
Rhinotracheitis, Bovine Respiratory Syncytial Virus, Bovine Viral 
Diarrhea Virus and/or Parainfluenza-3 virus). Suppression of the 
function of phagocytic cells in the lungs (both alveolar macrophages and 
neutrophils) is a primary factor in predisposing to bacterial infection 
(Roth, 1984). 
One of the potential host responses to the causative agents (virus, 
bacteria) of shipping fever is the local production and release of gamma 
interferon from antigen activated T lymphocytes (Friedman and Vogel, 
1983). Gamma interferon is known to have immunomodulatory activities. 
One of three main goals of this research involved looking at the 
influence of gamma interferon on neutrophil function. This glycoprotein 
is available in a highly pure form produced through recombinant DNA 
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technology. It was hoped that if gamma interferon was found to activate 
peripheral blood neutrophil function, it might be utilized as an 
immunomodulator to decrease initial viral infection or lessen secondary 
bacterial pneumonia. A review of the literature on the influences of the 
available recombinant cytokines on neutrophil function is presented in 
section I. Work on the influences of recombinant bovine gamma interferon 
on bovine neutrophil function is presented in section II. 
The second part of this research involved the evaluation of the 
molecular events (RNA/ protein synthesis, arachidonic acid metabolism) 
involved in the activation of neutrophil cytotoxicity and the inhibition 
of random migration by recombinant gamma interferon. The ability of 
gamma interferon to activate neutrophils and the molecular events 
involved in this process were also examined in neutrophils isolated from 
cattle immunosuppressed by glucocorticoid treatment (dexamethasone). 
This work is presented in section III. 
The third part of the research for this dissertation involved 
comparing the ability of bovine gamma interferon to activate bovine 
neutrophils to have enhanced antibody-independent cytotoxicity and the 
apparent lack of activation of human neutrophils by human gamma 
interferon to have this activity. This work is presented in section IV. 
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Explanation of the Dissertation Format 
An alternative format was used in this dissertation. There are four 
sections after the General Introduction, each of the sections is an 
individual paper. The first section is a review that will'be submitted 
for publication, the second section has been published in Cellular 
Immunology, the third section has been submitted for publication, and the 
fourth section will be submitted for publication. Finally, a general 
summary and discussion of the dissertation is included. 
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SECTION I: 
A REVIEW OF THE ACTIVATION OF NEUTROPHILS 
FOR ENHANCED FUNCTION BY RECOMBINANT 
CYTOKINES 
Maria J, Steinbeck and James A. Roth 
Department of Veterinary Microbiology and Preventive Medicine 
Iowa State University 
Ames, Iowa 50011 
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The neutrophil fulfills an important role in the response of the host 
to inflammatory stimuli by participating in the first line of defense 
against pathogenic bacteria and parasites. The importance of the 
neutrophil is dramatically shown by conditions of neutropenia (reduced 
numbers of circulating neutrophils) (Dale et al./ 1979) or severe 
neutrophil disfunction (reviews: Hill, 1984; Roberts and Gallin, 1983; 
Gallin et al., 1983; Gallin, 1981; Malech and Gallin, 1987; Rotrosen and 
Gallin, 1987). Either condition will result in severe, recurrent 
microbial infections. Clinical disease manifestations include: ulcers 
of the mucous membranes, otitis in childhood, frequent skin infections, 
severe gingivitis, periodontal disease, (Quie, 1982; Buescher and Gallin, 
1983; Gallin, 1985b; Van Dyke, Levine, and Genco, 1985; Charon, 
Mergenhagen, and Gallin, 1985; White and Gallin, 1986) and recurrent 
bouts of pneumonia and other types of life-threatening bacterial and 
fungal infections (review; Rotrosen and Gallin, 1987). 
The mature neutrophil (polymorphonuclear leukocyte or neutrophilic 
granulocyte) is completetly differentiated and incapable of proliferation 
(Altman, 1978). In the peripheral blood, these cells are distributed 
between freely circulating and marginal (adhered to vascular endothelium) 
pools (Cartwright, Athen, and Wintrobe, 1964), with approximately 50% in 
each pool. The half-life of the neutrophil in peripheral blood is on the 
average of 6-7 hours, which is a relatively short-time period compared to 
other circulating white blood cells, i.e., the half-life of lymphocytes 
or monocytes (Craddock, Perry, and Lawrence, 1956). At some point during 
senescence, the neutrophils are removed from the blood by macrophages in 
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the spleen (Wade and Mandell, 1983). Alternatively/ the marginated 
neutrophil can migrate into the tissues where it functions as a mobile 
phagocyte, surviving up to 4 to 5 days (Craddock, 1972). This directed 
migration into tissues occurs in response to a variety of inflammatory 
stimuli: infectious agents, formylated peptides (in some species), and 
host products generated in response to invading microorganisms. 
It is now recognized that neutrophils can be activated by cytokines 
to have enhanced function. This indicates that neutrophils serve as 
effector cells involved in cell-mediated immune responses. Cell-mediated 
immune reactions are mediated by mononuclear cells in response to 
specific antigens on the surface of infected or abnormal host cells. The 
antigen-stimulated cells release monokines and lymphokines that bind to 
specific receptors on the neutrophil and induce its activation. 
Activation enhances the ability of neutrophils to localize at sites of 
inflammation and to produce and release products that function to kill 
bacteria, virus-infected cells, neoplastic cells, (Babior, 1984; Clark, 
1983), and hyphal forms of certain fungi (Diamond, Krzesicki, and Jao, 
1978). The purpose of this review is to summarize the information 
available on activation of neutrophil function by cytokines. Since it is 
difficult to judge the purity of biochemically purified cytokines, this 
review will discuss data on recombinant cytokines. 
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NEUTROPHIL STIMULATION 
The function of the neutrophil involves several different events and 
can be divided into two stages of stimulation. Stage I includes events 
that take place in response to low concentrations of soluble/ 
inflammatory stimuli; granulocytopoiesis, adherence, diapedesis, 
emigration, and chemotaxis. Stage II events include attachment and 
ingestion (phagocytosis), degranulation, metabolic burst activity, 
killing and digestion which take place in response to higher 
concentrations of soluble mediators or phagocytosable particulates 
(Snyderman and Pike, 1984). The biological responses of the neutrophil 
induced after chemoattractant binding may be the result of increases in 
2+ 
the intracellular free Ca concentration, alone or in conjunction with 
the formation of 1,2-diacylglycerol vrfiich can activate protein kinase C 
(review: Snyderman, Smith, and Verghese, 1986; Snyderman and Pike, 1985; 
Rotrosen and Gallin, 1987). The activation of protein kinase C 
(phosphorylation) does not appear to be as important in neutrophil 
degranulation responses (Sha'afi et al., 1986; Salzer, Gerard, and 
McCall, 1986; Berkow, Dodson, and Kraft, 1987), but may play a role in 
superoxide anion production initiated by stimuli other than 
chemoattractants (Gerard et al., 1986; Berkow, Dodson, and Kraft, 1987). 
For the purpose of this review we will define neutrophil stimulators 
as those factors which cause a direct response from the neutrophil such 
as chemotaxis, ingestion, induction of the respiratory burst, or 
degranulation. We will define neutrophil activators as those substances 
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which enhance neutrophil responses to a stimuli. 
Granulocytopoiesis is the process of production and delivery to the 
bloodstream of an adequate number of mature granulocytes (neutrophils, 
eosinophils, and basophils). This process is normally regulated by 
hematopoietic growth factors called colony-stimulating factors (Stanley 
and Jubinsky, 1984) and/or interleukin-1, which has been reported to play 
a role in the increased release of mature neutrophils from the bone 
marrow during an acute-phase reaction (Craddock, Perry/ and Lawrence, 
1956). 
The circulating neutrophils and vascular endothelial cells are 
capable of responding to very low concentrations (~1 nM) of soluble 
inflammatory stimuli. These mediators (chemoattractants) bind to 
specific receptors (high-affinity) on the neutrophil membrane and 
initiate various biochemical events culminating in adherence, diapedesis, 
emigration, and directed migration into the infected tissues. The mature 
neutrophil is capable of increasing the surface expression of adherence 
proteins (iC3b receptor family) in response to low concentrations of 
chemoattractants (Todd et al., 1984). These proteins are in part 
responsible for weak adhesion to the vascular endothelium (margination) 
which must take place before directed migration can occur (Wilkinson, 
1974; Keller et al., 1979; Dahlgren, 1982). Investigation of patients 
with neutrophil iC3b deficiency has highlighted the importance of 
adherence for the biological responses of diapedesis, emigration, and 
chemotaxis. These patients are deficient in the beta-subunit that is 
common to iC3b receptor/Mol, LFA-1 and pl50,95, a family of structurally 
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and functionally related glycoproteins that mediate neutrophil adherence 
(Springer et al./ 1984; Anderson et al., 1985; Buescher et al., 1985). 
Other adherence-related neutrophil functions such as the attachment stage 
of phagocytosis and antibody-dependent cell-mediated cytotoxicity are 
also impaired (Kohl et al., 1984; reviews: Anderson and Springer, 1984; 
Buescher et al., 1985; Anderson et al., 1985). Patients with neutrophils 
lacking these receptors are susceptible to increased severe and recurrent 
infections (review: Anderson and Springer, 1984). 
Diapedesis or migration between endothelial cells of the capillary 
venules follows the adherence of the neutrophil to the endothelium. 
Diapedesis is assisted by the action of vascular permeability factors 
(e.g., histamine, serotonin, bradykinin, and activated-complement 
components, particularly C5a) released or formed during the inflammatory 
process (Wilkinson, 1974). Emigration through the vascular basement 
membrane is the final step in the process of entering the tissues. The 
neutrophils may affect this process by selectively releasing proteases 
(Olsson and Venge, 1980; Cochrane, 1977). After entering the tissues, 
directed migration of the neutrophil against a concentration gradient 
(chemotaxis) towards the site of chemoattractant production. 
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STAGE II OF STIMULATION 
As the neutrophils approach the origin of chemoattractants in the 
inflamed tissue, they are bombarded by a multiplicity of stimuli in 
addition to elevated levels of chemoattractants. The chemoattractants 
include soluble products of complement activation (particularly C5a) 
(Muller-Eberhard/ 1981), soluble bacterial products (Schiffmann et al., 
1975), host generated arachidonate metabolites (leukotrienes) (Robinson, 
Curran, and Hamer, 1982), and platelet activating factor (Naccache et 
al., 1986). At elevated concentrations the chemoattractants bind to low-
affinity receptors (Koo, Lefkowitz, and Snyderman, 1982; Naccache et al., 
1986; Goldman et al., 1987). In addition, phagocytosable particulate 
stimuli such as immune-complexes (Cochrane, 1977; Johnson and Ward, 1982) 
and antibody and complement-coated particles (opsonized particles) 
stimulate the neutrophil. Some soluble products in high concentrations 
can initiate specific functions of the neutrophil, (review: Spitznagel, 
1983) but generally the chemoattractants serve as activators, enhancing 
neutrophil responsiveness to a second particulate stimulus. Whereas, 
stimulation by particulate stimuli triggers neutrophil function without 
the need for an activator molecule. 
Stage II of stimulation results in induction of neutrophil 
phagocytosis, degranulation, and metabolic burst activity. Phagocytosis 
is a two stage process whereby the neutrophil selectively binds and then 
ingests the bound particle (Zakhireh, Block, and Root, 1979). 
Opsonization or coating of particles with antibody and/or complement 
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fragments (C3b, iC3b) allows the neutrophil to selectively bind these 
particles via specific receptors. Both the Fc (e.g., ® low-
affinity receptor which recognizes antigen-bound or aggregated IgG^) and 
C3b receptors (CRl) are present on the mature neutrophil surface (Roos et 
al., 1981). Once bound via the receptor, the particle triggers local 
infolding of the neutrophil membrane as a result of the contraction of 
actin and myosin filaments attached to cytoplasmic microtubules, and 
draws the particle into an enclosed vacuole called a phagosome. It has 
been suggested after observations of some patients with neutrophil iC3b 
receptor (CR3) deficiency that the CR3 receptor may play a role in the 
modulation of cytoskeleton assembly and therefore effect the associated 
function of other cell surface receptors (i.e., C3b and Fc) (Arnaout et 
al., 1983). Very soon after or simultaneously with the attachment of the 
particle to the neutrophil, several morphological and biochemical events 
are set into motion which may result in the destruction of the ingested 
microorganism. These post-phagocytic events involve; 1. delivery of 
the hydrolytic enzymes and cationic proteins into the phagosome, a 
process termed degranulation, 2. formation of highly reactive oxygen 
radicals through a coordinated series of metabolic events termed the 
"respiratory burst", and 3. actual killing and digestion of the microbe. 
A variety of antimicrobial mechanisms are involved in this final step and 
indicate that neutrophils have an appreciable reserve capacity if one 
mechanism is impaired (Zakhireh, Block, and Root, 1979). 
Degranulation refers to the release of granule contents either 
extracellularly or into the phagosome from two types of granules (in most 
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species that have been studied). Neutrophils from some species contain a 
third type of granule, which has been defined in the bovine and other 
ruminants to contain predominantly cationic proteins (Gennaro et al./ 
1983). In human neutrophils a gelatinase containing tertiary granule has 
been identified (Dewald et al., 1982). The two most characterized 
granules are the primary (azurophil) and secondary (specific) granules, 
literally, the first and second granule types made at early stages of 
neutrophil differentiation (Sainton, Ullyot, Farquhar, 1971). Primary 
and secondary granules are morphologically distinct, contain some common 
but generally unique components, and each granule type releases its 
contents under separate control mechanisms (Bainton and Farquhar, 1968; 
Sainton, 1973). Primary granules contain myeloperoxidase, a variety of 
acid hydrolases, and neutral proteases involved in the killing and 
digestion of phagocytosable organisms or the destruction of 
nonphagocytosable fungi or abnormal cells (Goldstein, 1975). Other 
components of human neutrophil primary granules that may have direct 
microbicidal activity, include cationic proteins which bind to or 
permeabilize membranes (Zeya and Sptiznagel, 1956; Odeberg and Olsson, 
1975; Drazin and Lehrer, 1977; Weiss et al., 1978) and lysozyme 
(Strominger and Ghuysen, 1967; review; Baggiolini, 1972). Approximately 
one-half to two-thirds of the lysozyme is contained in the secondary 
granules. This enzyme digests the peptidoglycan portion of the bacterial 
cell wall (review: Spitznagel et al., 1974). Adult bovine neutrophils 
are devoid of granules containing measurable lysozyme activity, although 
neutrophils isolated from young calves (10 days to 6 weeks of age) 
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apparently contain this activity (Bielfeldt-Ohmann and Babiuk, 1984). 
Secondary granules are often called specific granules because they are 
characteristic of the mature neutrophil and aid in identification of the 
neutrophilic granulocyte after Wrights-Giemsa staining. These granules 
also contain lactoferrin (a microbiostatic protein that chelates iron 
which is required by some bacteria and fungi for growth) (Baggiolini, de 
Duve, and Masson, 1970) collagenase, and vitamin-B^g binding protein 
(whose function is unknown). In addition, the specific granules contain 
monocyte chemotactic molecules and some substance(s) capable of 
generating the active complement fragments C3a and C5a. 
It was originally believed that secondary granules were also the 
intracellular store for the adherence proteins (CR3) and other surface 
receptors (e.g., CRl). However, degranulation of secondary granules does 
not take place at the low chemoattractant concentrations that cause up-
regulation of these receptors (Burger et al., 1984; Petrequin et al., 
1986; O'Shea et al., 1985; Parkos et al., 1985). Nor do the kinetics of 
translocation of these molecules to the cell surface fit within the time 
frame of degranulation of secondary granules. More recently, another 
granule-like compartment has been separated from human neutrophils by 
density centrifugation. This mobilizable, intracellular compartment 
fuses with the surface neutrophil membrane and up-regulates surface 
alkaline phosphatase activity in response to nanomolar concentrations of 
chemoattractants. 
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Therefore/ there may be yet another compartment containing alkaline 
phosphatase activity that serves as the intracellular store for iC3b, 
C3b/ and other surface receptors (Borregard et al., 1987). 
The killing and digestion by activated neutrophils can be divided 
into oxygen-independent and -dependent mechanisms/ which are separate but 
co-functioning processes (Klebanoff/ 1975; Klebanoff et al., 1985). 
i. Oxygen-independent killing effectors include constituents of both 
primary and secondary granules/ e.g., proteases, lysozyme/ lactoferrin/ 
and cationic proteins (defensins and bactericidal permeability inducing 
protein). Patients with chronic granulomatous disease have various 
inherited severe defects in the oxidative metabolic effector system and 
their neutrophils affect killing only through oxygen-independent 
mechanisms (reviews; Rotrosen and Gall in/ 1987; Malech and Gall in/ 
1987). The neutrophils from these patients are still capable/ although 
to a variable extent/ of killing micoorganisms (Spitznagel/ 1977; review: 
Root and Cohen/ 1981). The CCD patients are often afflicted with 
increased frequency/ severity/ and duration of infections with catalase-
positive bacteria and fungi (Gallin and Fauci/ 1983; Gallin et al./ 1983; 
Tauber et al./ 1983). The increased duration of infections is the result 
of defective neutrophil resolution of the inflammatory process/ which is 
dependent on oxidative product inactivation of soluble inflammatory 
stimuli including prostaglandins/ formyl peptides/ C5a/ and leukotrienes 
(Clark and Klebanoff/ 1979; Henderson and Klebanoff/ 1983). Defective 
oxygen-independent killing occurs in neutrophils from Chediak-Higashi 
syndrome patients (human and animal) as a result of defective packaging 
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and/or release of granule constituents (Klebanoff and Clark, 1978). 
Humans with specific granule deficiencies due to production defects also 
have decreased oxygen-independent killing (reviews: Malech and Gallin, 
1987; Rotrosen and Gallin, 1987). The CHS and specific granule deficient 
patients have depressed inflammatory responses and suffer from severe 
recurrent bacterial infections (Gallin, 1985a). Therefore, both oxygen-
dependent and -independent killing are required for a complete arsenal 
against all invading microorganisms. 
ii. Oxygen-dependent killing depends on the initial generation of 
superoxide anion by the neutrophil during the respiratory burst. 
Molecular oxygen is converted by NADPH-oxidase (an intergal-membrane, 
multi-component enzyme complex) to superoxide anion; 20^ + NADPHg — 20" 
.g + NADPH + H^. Superoxide anion itself has little direct toxic effect 
on microorganisms, (Goldstein et al., 1977; Babior, 1978) but acts as a 
precursor from which hydrogen peroxide, hydroxyl radicals, and singlet 
oxygen are derived. The formation of these direct microbicidal effectors 
occurs via the Haber-Weiss reaction: Og"' + HgOg — ^ 0^ + OH* + OH" 
(Root and Metcalf, 1977; Klebanoff, 1975). Most of the generated 
hydrogen peroxide is utilized in the MPO-HgOg-halide system. The MPO-
H202-halide system affects a part of the oxidative killing of bacteria, 
fungi, viruses, mycoplasma, and tumor cells (Klebanoff, 1967; Klebanoff 
and Clark, 1978). Myeloperoxidase binds available hydrogen peroxide and 
oxidizable halide cofactors to the microbial target surface. The MPO-
catalyzed reaction: halide(~) + H"*" + HgOg — (halide)HO~ + H^O generates 
toxic hypochlorous acid (H0C1~) (Harrison and Schultz, 1976) or damaging 
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iodination of viccinal proteins of the bacterial cell wall/ if iodide is 
available (Babior, 1978; Klebanoff, 1967). Myeloperoxidase deficiencies 
in human phagocytes result in a slower rate of microbicidal activity 
(review; Rotrosen and Gallin, 1987). 
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IMMUNE CELL INTERACTION AND ACTIVATION OF NEUTROPHILS BY CYTOKINES 
Cytokines include factors produced and released by cells of the 
immune system activated during cell-mediated immune responses. Some of 
these factors are also released by nonimmune cells in the immediate area 
of inflammation and in the bone marrow stroma. Because activated immune 
cells generally secrete more than one cytokine in response to an 
appropriate stimulus/ it has been difficult to evaluate the direct 
effects of the individual cytokines. Recombinant DNA technology has 
provided the ability to clone the gene for each protein and allowed for 
the evaluation of the direct effect of each factor. The availability of 
recombinant cytokines has also allowed the use of a defined mixture of 
cytokines to determine the potential synergy in their abilities to 
modulate immune cell functions and the immune response. The cytokine 
genes that have been cloned from cells of one or more animal species 
include: colony-stimulating factors, interleukins, tumor-necrosis 
factors, and interferons. This part of the review will cover what is 
known about the modulatory effects of the individual recombinant 
cytokines on mature neutrophil microbicidal and cell-mediated functions. 
18 
COLONY-STIMULATING FACTORS 
The growth of hematopoietic progenitor cells in semisolid media lead 
to the discovery that cell division and differentiation were regulated by 
specific protein factors (Pluznik and Sachs, 1965). These specific 
proteins were called hematopoietic colony-stimulating factors (CSFs) 
because their activity was identified in cell culture colony formation 
assays (Ichikawa, Pluznik, and Sachs, 1966; Bradley and Metcalf, 1966; 
Clark and Kamen, 1987). As mentioned earlier in this review, colony-
stimulating factors and interleukin-1 are involved in normal and acute-
phase reaction induced granulocytopoiesis. In the low picomolar range, 
all of the CSPs stimulate hematopoietic progenitor cells to form colonies 
in soft agar culture. In the murine system, four major types of CSFs 
have been identified, granulocyte (G)-CSF, monocyte (M)-CSF, granulocyte-
monocyte CSF (GM)-CSP, and multi-CSF (IL-3), and analogous factors have 
been described in the human system (Pluznik and Sachs, 1965; Metcalf, 
1985; Metcalf, 1986; Yang et al., 1986) with the possible exception of 
multi-CSF (Nicola, 1987). These are not the only hematopoietic growth 
factors, although these are all that are known to influence 
granulocytopoiesis. 
Granulocyte (G)-CSF and monocyte (M)-CSF (CSF-1) are postulated to 
support the growth (survival), proliferation, and differentiation of only 
relatively late progenitor granulocytes or monocytes already committed to 
their respective lineages (Metcalf and Nicola, 1983; Stanley and Heard, 
1977). Granulocyte-monocyte (GM)-CSP or CSF-2 interacts with myeloid 
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precursors which are still able to differentiate into neutrophils, 
eosinophils or monocytes (Metcalf, 1986). Multi-CSF/ interleukin-3 (IL-
3)/ or CSF-3 is a multipotent CSP, which controls the differentiation of 
all cells of the immune system (Schrader, 1986). 
The individual CSF mRNAs can be detected by hybridization techniques 
using cDNA probes and are found to be selectively expressed in several 
different cell types after activation. Monocytes activated by endotoxin 
or interferon-gamma (released during CMI responses) express high levels 
of mRNA for G- and M-CSP but not GM-CSF (Ramaldi, Young, and Griffin, 
1987). Antigen-stimulated T cells contain relatively high levels of GM-
CSF mRNA (Wong et al., 1987) and perhaps low levels of IL-3 mRNA (Yang et 
al., 1986) but do not express the mRNAs for either G- or M-CSF (Ramaldi, 
Young, and Griffin, 1987). Other cytokines released from monocytes 
activated during immune responses, interleukin-1 and tumor necrosis 
factor-alpha, activate cells present in the bone marrow stroma to express 
G- and GM-CSF mRNA (review; Clark and Kamen, 1987). 
The genes encoding the four major murine and human myeloid growth 
factors have all been cloned in mammalian cells and sequenced (Nicola, 
1987; Clark and Kamen, 1987). Approximately 70% cross-species homology 
in nucleotide sequence of the protein-coding region of the murine (mu) 
GM-CSF cDNA and human (hu) GM-CSF cDNA exists (Wong et al., 1985). 
Whereas, murine IL-3 and human IL-3 lack sequence homology, but have 
similar structural properties (Yang et al., 1986; Miyatake et al., 1985). 
Human GM-CSF is an acidic glycoprotein with a relative molecular mass 
(Mr) of 22,000 (Gasson et al., 1984). Similarly, IL-3 is a glycoprotein 
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with a Mr of 28/000 (Ihle et al., 1982). Human GM-CSF and IL-3 have some 
common biological activities, some common structural features, and are 
both expressed in activated T cells, but no significant nucleotide 
sequence homology exists for these two products (Clark and Kamen, 1987). 
Immunochemical analysis of natural huGM-CSF implies that recombinant 
factors produced in mammalian cells (Chinese hamster ovary cells or 
monkey COS-1 cells) have structures very similar to the natural 
molecules. Both natural and recombinant huGM-CSF (Donahue et al., 1985) 
or huIL-3 (Clark and Kamen, 1987) expressed in monkey COS-1 cells are 
extremely heterogeneous in size. The different molecular weight forms of 
these proteins can be accounted for by varying degrees of glycosylation. 
Interestingly, the higher the degree of glycosylation the less active the 
rhuGM-CSF molecule in in vitro assays (Clark and Kamen, 1987). In vivo 
glycosylation appears to affect the rate and extent of distribution 
throughout the fluids and tissues of the rat, but does not appear to play 
any role in the rate of clearance of GM-CSF. 
Granulocyte-CSF is less glycosylated and therefore less heterogeneous 
in size distribution (Clark and Kamen, 1987). When expressed in E. coli, 
huG-CSP lacks carbohydrate additions and is biologically active both in 
vivo and in vitro (Welte et al., 1987). 
Murine multi-CSF and murine or human GM-CSF receptor numbers are low 
and decrease to a few 100/neutrophil during cell maturation (Gasson et 
al., 1984; Nicola and Metcalf, 1986). Even though there are low numbers 
of receptors, GM-CSF binding to the neutrophil plasma membrane has been 
shown to be specific. Receptors for murine and human G-CSF are specific, 
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have a single affinity/ and occur on all cells of the neutrophilic 
granulocyte cell series. Murine neutrophil G-CSF receptor numbers 
increase during cell maturation to a few 100/cell (Byrne, Guilbert, and 
Stanley, 1981; Nicola and Metcalf, 1985) and human neutrophil receptor 
numbers decrease slightly with cell maturation (Gasson et al., 1985; 
Clark and Kamen, 1987). Uniquely among the four murine CSFs, G-CSF for 
man or mouse binds to receptors on cells from either species, which has 
allowed for the definition of G-CSF receptor distribution in human cells 
(Nicola, Begley, and Metcalf, 1985). Colony-stimulating factor binding 
to specific receptors leads to a decrease in cell surface receptor number 
as the CSF-receptor complex is internalized and degraded. In addition, 
the binding of some murine CSFs to their specific receptors decreases the 
number of available receptors for other CSFs as well (trans-modulation) 
(Nicola, 1987). Less work has been done to examine trans-modulation of 
CSF receptors on human neutrophils, although one report suggests a 
similar process takes place (Nicola, Vadas, and Lopez, 1985). Trans-
modulation occurs at moderate to high concentrations of a CSF and may 
account for the induction of biological activities other than those 
attributed to the bound CSF (Zachary and Rozengurt, 1985; Walker et al., 
1985). Nicola (1987) recently reviewed the trans-modulation of CSF 
receptors and offered several possible explanations of the biological 
significance. 
In general, the biological activities induced by recombinant huG-CSF 
and GM-CSF are in agreement with those of the natural products (Clark and 
Kamen, 1987). Recombinant huGM-CSF stimulates the proliferation of human 
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granulocyte-monocyte progenitor cells, leading to typical colony 
formation in semi-solid agar cultures (40-200 U/ml) (Metcalf et al., 
1986b). This cytokine also increases the survival of mature neutrophils 
by several hours (Lopez et al., 1986). In addition, rhuGM-CSP up-
regulates the surface expression of the adherence glycoproteins, GFA-1, 
GFA-2, and Mol without changing the expression of betag-microglobulin 
within an hour after rhuGM-CSP addition (80 U/ml) (Lopez et al., 1986). 
The selective up-regulation does not result in increased adherence of 
rhuGM-CSF treated neutrophils to either plastic or human umbilical vein 
endothelial (HUVE) cells. These authors did not address the apparently 
contradictory findings. Superoxide anion production in response to FMLP 
was increased (as determined by the cytochrome c assay) in neutropils 
pre-incubated in rhuGM-CSF (Weisbart et al., 1985; Lopez et al., 1986, 
1987). Pretreatment of the neutrophils for 120 minutes with rhuGM-CSF 
before adding the FMLP was necessary to see a maximal increase in 
superoxide anion production. Other effects of rhuGM-CSF addition (8 to 
80 U/ml) included a dose-dependent increase in phagocytosis of 
Saccharomyces cerevisiae in a one hour assay (Metcalf et al., 1986b; 
Lopez et al., 1986, 1987). An increase in induced lysozyme release 
occurred only after pretreatment with cytochalasin B, followed by the 
simultaneous addition of 80 U/ml of rhuGM-CSF and FMLP (Lopez et al., 
1986). Recently, questions have been raised as to whether the addition 
of cytochalasin B may affect neutrophil function directly, making the 
interpretation of these results difficult. There was little direct 
increase in the MPO-HgOg-halide activity (iodination assay) induced by 
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rhuGM-CSF (80 U/ml) or unopsotiized zymosan but together they enhanced 
iodination to a significantly greater value than either alone (Lopez et 
al./ 1986). Recombinant huGM-CSF enhanced neutrophil ADCC activity 
against ^^Cr-labeled p815 mouse mastocytoma cells in a 2 to 2.5 hour 
assay (Metcalf et al., 1986b; Lopez et al., 1986, 1987). The activities 
attributed to the recombinant GM-CSF expressed in E. coli were not due to 
a contaminating E. coli cell wall component (LPS) which was present at < 
0.2 ng/ml in the assays after dilution. The only effect of a higher 
concentration of exogenous E coli LPS (1 ng/ml) on neutrophil function 
was an increase in adherence which was not measurable after rhuGM-CSF 
addition. 
Compared to GM-CSF, relatively little research has been conducted on 
the influence of the other CSFs on neutrophil function. Recombinant 
human granulocyte (G)-CSF exhibits colony-stimulating activity in agar 
cultures and induces granulocyte differentiation of premature neutrophils 
(1 X 10^ U/ml) (Souza et al., 1986). Little work has been done or 
published on the effects of G-CSF on mature neutrophil function from any 
species. Recombinant primate multi-CSF (IL-3) induces granulocyte 
colonies but has thus far proved to be an activating factor for only 
mature human eosinophils and not neutrophils (ingestion, ADCC, superoxide 
anion production) (Lopez et al., 1987). Murine IL-3 induces granulocyte 
colonies but had no effect on the activity of either mature murine 
eosinophils or neutrophils (Metcalf et al., 1986a). 
In vivo administration of rhuGM-CSF to neutropenic patients with AIDS 
resulted in a dose-dependent increase in the white blood cell count. 
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correcting the neutropenia (Clark and Kamen, 1987). The highest doses 
actually caused leukocytosis. The neutrophil functions were not 
examined. In contrast, rhuG-CSF administration to normal monkeys twice 
daily via a subcutaneous route increased the white blood cell count but 
required continuous administration. No increase in neutrophils was 
observed/ but there was an increased number of circulating T cells (Welte 
et al./ 1987). Neutrophils from the rhuG-CSF treated monkeys 
demonstrated an enhanced ability to kill and phagocytose bacteria in 
vitro. 
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Table 1. Influence of recombinant GM-CSF on neutrophil function 
in vitro 
Increases: 
Proliferation of granulocyte-
monocyte progenitors 
J^eutrophil survival 
Expression of GFA-1/ GFA-2/ 
. and Mol 
Superoxide anion production 
. in response to stimulus 
^Phagocytic activity 
I^Lysozyme release 
MPO-H-O.-halide activity 
in response to stimulus 
^Cytotoxicity (ADCC) 
^Neutrophil numbers in peripheral 
blood after in vivo admin. 
to AIDS patients 
Phagocytic and bactericidal activity 
after in vivo admin, to monkeys 
Unaffected: 
(Metcalf et al./ 1986b) 
(Lopez et al., 1986) 
(Lopez et al., 1986) 
(Weisbart et al., 1985; 
Lopez et al., 1986, 1987) 
(Metcalf et al., 1986b; 
Lopez et al., 1986) 
(Lopez et al., 1986) 
(Lopez et al., 1986) 
(Metcalf et al., 1986b; 
Lopez et al., 1986) 
(Clark and Kamen, 1987) 
(Welte et al., 1987) 
.Expression of beta_-microglobulin 
Adherence 
""^Neutrophil numbers after in vivo 
admin, to monkeys 
(Lopez et al., 1986) 
(Lopez et al., 1987) 
(Welte et al., 1987) 
(superscripts indicate neutrophils isolated from (h)humans and 
(mo)monkeys treated with GM-CSP from the same species) 
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INTERLEUKIN-1 
The term interleukin (IL) was first proposed in 1979 to describe two 
secreted leukocyte products with similar Mr of 15-17,000 (review; 
Dinarello and Mier, 1986). The term interleukin was adopted since both 
IL-1 and IL-2 were produced by and acted on leukocytes. Interleukin-1 
(IL-1) was the name given to the macrophage product, called T and B 
lymphocyte-activating factor, which has a number of biological activities 
including modulation of neutrophil function. 
Production of IL-1 is part of the host's response to challenges, such 
as microbial invasion, injury, immunological reactions, neoplastic 
changes, and inflammatory processes. During these responses IL-1 is 
released from a variety of cells and has multiple effects on a broad 
range of cell targets (Root and Wolff, 1968; Atkins et al., 1972; Gery, 
Gershon, and Waksman, 1972; Gery and Waksman, 1972; Unanue, 1978; 
Rosenthal, 1980; Oppenheim and Gery, 1982). IL-1 induces fever (pyrogen) 
and it can mediate several components of the host's systemic acute-phase 
responses to a variety of challenges. These responses are characterized 
by alterations in metabolic, endocrinologie, neurologic, and immunologic 
functions (Kampschmidt and Pulliam, 1978; Rosenwasser and Dinarello, 
1981). It has been suggested that IL-1 is the factor responsible for the 
neutrophilia associated with the acute-phase reaction (Craddock, Perry, 
and Lawrence, 1956). This results from an increased release of mature 
neutrophils from the bone marrow reserve (Kampschmidt, 1984). 
Interleukin-1 is secreted in two forms with different isoelectric 
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points (pis) of 7.0 (IL-1 beta) (Auron et al., 1984; March et al., 1985; 
Gray et al., 1986) and 5.0 (IL-1 alpha) (Lomedico et al., 1984). The IL-
Is are products of two separate genes, bearing little homology at the 
protein or DNA level, yet possessing highly conserved biological 
activities and structural features (Dinarello, Goldin, and Wolff, 1974; 
Bodel, 1978; Cebula et al., 1979; Rosenwasser, Dinarello, and Rosenthal, 
1979; Lachman and Metzger, 1980). Across species, murine and human IL-1 
alpha share 80% homology at the amino acid level (Auron et al., 1985). 
Resting macrophages are devoid of IL-1 mRNA and protein but upon 
stimulation with endotoxin or after adherence in vitro, there is a 
transient one hour to five day increase of IL-1 alpha and beta mEysiAs to 
similar levels (Fuhlbrigge et al., 1987). By four hours, IL-1 can be 
found as an intracellular, membrane, and extracellular protein (Hanson, 
Murphy, and Windle, 1980; Kurt-Jones et al., 1985; Kurt-Jones, Virgin, 
and Unanue, 1986; Matsushima et al., 1986). 
Recombinant huIL-1 beta induces lymphocyte activation, but has no 
effect in several assays of mature neutrophil function. It is important 
to point out that the neutrophils did respond normally to other 
stimulants. Recombinant huIL-1 beta did not act as a chemotactic factor 
for neutrophils nor did it alter the neutrophil chemokinetic activity. 
Superoxide anion generation was not directly stimulated by 1, 10, or 100 
ng/ml of rhuIL-1 beta (cytochrome c assay) (Georgilis et al., 1987). At 
the same concentrations rhuIL-1 beta was unable to directly stimulate the 
release of lysozyme or enhance phagocytosis of S. aureus at a 20:1 ratio 
(number of bacteria per neutrophil) over a time period of 5, 10, 20, or 
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30 minutes. The physiological dose range for IL-1 is below 10 ng/ml, 
suggesting that sufficient concentrations of IL-1 were added to the 
assays. Therefore, most of the activities originally ascribed to IL-1 
activity on PMN function in nonhomogenous preparations were probably due 
to contamination with tumor necrosis factor, which enhances phagocytosis 
(Shalaby et al., 1985) and is a weak, direct stimulus of the respiratory 
burst and induced lysozyme release (Klebanoff et al., 1986). It has also 
been reported that IL-1 affects the intracellular cytosolic-free calcium 
concentration [Ca"*"*"]^ and might stimulate neutrophils via this second 
messenger. Using Quin 2 fluorescence as a measure, resting [Ca"*""*"]^ was 
unaffected by rhuIL-1 beta at concentrations of 1, 10, 100 ng/ml 
(Georgilis et al., 1987). In vivo, both forms of human recombinant IL-1 
produce a typical monopiasic fever at rabbit pyrogenic doses of 50 to 200 
ng/kg (Dinarello, 1986; Dinarello et al., 1986). It therefore appears 
that the IL-ls have biological activity but do not effect neutrophil 
functions as evaluated by these particular assays. 
In vivo recombinant human IL-1 alpha has been shown to increase the 
survival rate of mice challenged with Pseudomonas aeruginosa or 
Klebsiella pneumoniae (Ozaki et al., 1987). Based on the rhuIL-1 beta 
results, this is probably not due to a direct effect of IL-1 alpha on 
neutrophil function. This does not rule out the possibility that 
neutrophils were activated by another cytokine whose induction was 
mediated by IL-1 alpha. 
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Table 2. Influence of recombinant IL-1 beta on neutrophil function 
in vitro 
Increases: 
"^Body temperature after in vivo 
admin, to mice (both IL-1 beta 
and alpha) 
m, Survival after bacterial challenge 
(in vivo admin, to mice) 
(Ozaki et al./ 1987) 
(Ozaki et al., 1987) 
Unaffected: 
'^Intracellular free Ca"* 
concentration 
(Georgilis et al., 1987) 
. Chemokinesis 
.Superoxide anion production 
^Phagocytic activity 
Lysozyme release 
(Georgilis et al., 1987) 
(Georgilis et al., 1987) 
(Georgilis et al., 1987) 
(Georgilis et al., 1987) 
(superscripts indicate neutrophils isolated from (h)humans and 
(m)mice treated with IL-1 beta from the same species) 
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TUMOR NECROSIS FACTORS 
Tumor necrotizing factor activity was first described by O'Malley et 
al. (1962) in the serum of mice challenged with endotoxin obtained from 
Serrâtia marcesceng. In 1975/ Carswell et al. injected bacillus 
Calmette-Guerin (BCG) and later endotoxin into mice, rats, and rabbits 
and described a similar tumor necrosis factor activity in serum. This 
factor appeared in the serum within hours, caused regression of some 
transplanted tumors in vivo, and was cytostatic or cytocidal to some 
tumor cells in culture but had no effect on normal human fibroblasts. 
The mediator was thought to originate from macrophages and was termed 
tumor necrosis factor (TNF) also identified as cachectin (Buetler, 
Milsark, and Cerami, 1985; Buetler et al., 1985). 
Two TNFs have now been described; 1. TNF-alpha (cachectin) a 
soluble protein (17kD) product secreted predominantly from macrophages 
activated by endotoxin, BOG, lectin, or IL-2, and to a lesser extent 
activated NK cells, natural cytotoxic cells and IL-3 dependent bone 
marrow derived mast cells and 2. TNF-beta (also called lymphotoxin), a 
secreted glycoprotein (25kD) product of lymphoblastoid cells (Granger et 
al., 1970; Pennica et al., 1984; Gray et al., 1984; Aggarwal et al., 
1984; Aggarwal, Moffat, and Harkins, 1985) and antigen- or mitogen-
activated T cells (Granger and Kolb, 1968). The TNFs are products of 
different genes, produced by different cell types, but with approximately 
30% amino acid homology and similar functions (Pennica et al., 1984). 
Human TNF-alpha and -beta and murine TNF-alpha have been produced in 
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highly purified forms by recombinant DNA technology (Pennica et al., 
1984; Gray et al., 1984; Wang et al., 1985; Pennica et al., 1985). 
Natural TNF-alpha is not glycosylated, in contrast to TNF-beta which is 
glycosylated. Glycosylation of the recombinant TNFs is absent if E. coli 
is used as an expression vector. However, the lack of glycosylation 
appears to be unimportant for biological activity. Tumor necrosis factor 
activity is usually expressed as units of antitumor activity. The 
biological assay for TNF cytolytic activity is calculated as a titer of 
TNF induced cytolytic activity for actinomycin D-treated L929 mouse 
fibroblast cells (Aggarwal et al., 1984). 
The action of TNF on neutrophils appears to require initial binding 
to surface receptors (Rubin et al., 1985; Kull et al., 1985). The 
binding of I-rhuTNF-alpha to human neutrophils reaches maximal values 
in 30 minutes at 37°C (Shalaby et al., 1987). There are approximately 
6000 receptors per cell (Scatchard analysis) and the dissociation 
constant (Kd) is 1.37 nM. Neutrophils appear to express a single class 
of specific, high-affinity receptors that are probably internalized and 
degraded after TNF binding (Tsujimoto, Yip, and Vilcek, 1985; Shalaby et 
al., 1987). More recent observations indicate that rhuTNF-alpha and 
-beta compete for the same cellular receptor (Aggarwal, Eessalu, and 
Hass, 1985; Shalaby et al., 1987). 
The antitumor activity of TNF has been well established, although, 
the exact mechanisms mediating the in vitro and in vivo cytolytic 
activities of TNF-alpha and -beta are not well characterized. The 
ability of these cytokines to activate neutrophils and increase their 
32 
adherence and post-adhesion activities on vascular endothelial cells has 
been implicated as one possible mechanism that mediates a part of the 
hemorrhagic necrosis of solid tumors and the associated inflammation 
(Klebanoff et al., 1986; Shalaby, Pennica, and Palladino, 1986; Naworth 
and Stern, 1986; Shalaby et al., 1987; Palladino et al., 1987). 
Recently, the effects of both recombinant human TNF-alpha and -beta on 
the mature neutrophil have been published. In general, rhuTNF-alpha 
enhances the adhesion of human peripheral blood neutrophils to human 
umbilical-vein-derived endothelial (HUVE) cell monolayers in culture 
(Gamble et al., 1985). In addition, it has been reported that rhuTNF-
alpha activated neutrophils disrupt HUVE cells and cause inhibition of 
their proliferative activities (Shalaby et al., 1987), which could be 
important in tumor necrosis and inflammatory reactions. The increased 
TNF-mediated adherence is possibly due in part to translocation of the 
iC3b (CR3) receptor/adherence glycoprotein from intracellular stores to 
the surface membrane of neutrophils and in part to TNF effects on the 
endothelial cells (Todd et al., 1984; Gamble et al., 1985). This 
correlates with the fact that TNF effects on neutrophils are rapid 
(maximal within 5 minutes) and appear to be independent of protein and 
nucleic acid synthesis (Gamble et al., 1985). Neutrophils from 
individuals with deficiencies in the surface-adherence antigens do not 
adhere well to HUVE cells, indicating that these molecules are important 
for optimal adherence (Harlan et al., 1985). The increased expression of 
surface adherence proteins on neutrophils by rhuTNF-alpha treatment was 
detected with murine IgG monoclonal antibodies (mAb) 60.1 and 60.3 
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(Beatty et al., 1983; Klebanoff et al., 1985) which recognize different 
epitopes on the CR3 surface-antigen complex. Addition of either of these 
mAbs to neutrophils blocks resting or TNF-stimulated adherence, but has 
no effect on endothelium (HUVE cells lack antigen recognized by mAb 
60.3). Neutrophils incubated with 100 U/ml of rhuTNF-alpha have a 2-fold 
and 1.5-fold increase in expression of surface antigen recognized by mAbs 
60.1 and 60.3, respectively (Gamble et al., 1985), as determined by flow 
cytometry. Recombinant huTNF-alpha inhibits the migration of neutrophils 
under agarose at 100 U/ml of antitumor activity, the same concentration 
required for the increase in expression of the CR3 complex and within the 
range of the dose-dependent increase in adhesion (1 x 10®"^ U/ml); these 
could be related events (Gamble et al., 1985; Shalaby et al., 1987). 
Recombinant huTNF-alpha has been reported to be a weak but direct 
stimulus of the neutrophil MPO^HgOg-halide activity (Klebanoff et al., 
1986) and superoxide anion production of the neutrophil (Shalaby et al., 
1987). The addition of a second stimulus, unopsonized zymosan or FMLP, 
to the iodination assay or cytochrome c assay, respectively, resulted in 
greater than additive increases in both activities. The concentration 
range of TNF-alpha used was from 2 to 200 U/ml, these concentrations 
resulted in a dose-dependent increase in neutrophil respiratory burst 
activities in the presence of unopsonized zymosan. Monoclonal Abs 60.1 
and 60.3 (Beatty et al., 1983; Klebanoff et al., 1985; Arnaout et al., 
1984) inhibit the combined TNF, unopsonized zymosan induced enhancement 
of the MPO-HgOg-halide activity of neutrophils by inhibiting adhesion and 
subsequent phagocytosis of unopsonized zymosan. Monoclonal antibodies to 
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other neutrophil surface antigens had no effect on MPO-HgOg-halide 
activity under these assay conditions. 
Pretreatment of neutrophils for 15 minutes with rhuTNF-alpha or 20 
minutes with rhuTNF-beta resulted in increased phagocytic activity of the 
neutrophils. The increase in phagocytosis by rhuTNF-alpha (50 U/ml) was 
impressive, ingestion increased from 6 zymosan particles/100 neutrophils 
to 395 after 20 minutes and 464/100 neutrophils after one hour (Klebanoff 
et al., 1986). At 10 to 100 U/ml both recombinant or biochemically 
purified TNF-beta significantly increased, in a dose-dependent manner the 
ingestion of 1.5 um fluoresceinated latex beads by neutrophils as 
determined by flow cytometry (Shalaby et al., 1985). 
Recombinant huTNP-alpha (50 U/ml) increased secondary degranulation 
directly as measured by the release of lysozyme in the absence of another 
stimulus and greater than additive with zymosan (Klebanoff et al., 1986). 
Direct TNF induced release of MPO or beta-glucuronidase was equivalent to 
the release of LDH, a cytosolic enzyme that correlates with cell lysis. 
Shalably et al. (1985) have also reported that rhuTNF-alpha or -beta 
(100 U/ml) increased neutrophil-mediated ADCC against chicken 
erythrocytes (CRBC) after a two hour pretreatment. However, Perussia et 
al. (1987) reported that 40 or 80 U/ml of rhuTNF-beta were toxic for 
human neutrophils and only 5 U/ml were required to increase neutrophil 
ADCC using p815y targets in a 3 hour ^^Cr-release assay. In their assay, 
no pretreatment was needed and the enhanced activity was lost by 18 hours 
after the start of treatment. In addition, this enhancement apparently 
did not require the induction of (high-affinity receptor binds 
monomeric IgG) receptors that have been proposed to play a role in 
enhancement of neutrophil ADCC activity (Perussia et al./ 1987). More 
work needs to be done on the effects of rhuTNF-beta on neutrophil 
function and the possible toxicity at 40 or 80 U/ml needs to be further 
evaluated. 
Different cytokines have been used in combination to look for synergy 
in the enhancement of neutrophil function. Recombinant huTNF-alpha 
(Perussia et al., 1987) does not enhance ADCC by itself after 18 hours of 
incubation. Pretreatment of the neutrophils for 18 hours with rhuIFN-
gamma (200 U/ml) followed by washing and addition of rhuTNF-alpha into a 
3 hour assay lead to a greater enhancement than with rhuIFN-gamma alone. 
The possibility of contaminating molecules in the recombinant TNF 
preparations, in particular E. coli LPS, being responsible for the 
enhancement of neutrophil function has been eliminated in several 
different ways; 1) The TNF was heated to destroy TNF activity without 
destroying contaminating LPS (~5 ng/ml original product) activity, 2) the 
direct effects of exogenous E. coli LPS on various neutrophil functions 
was examined, and 3) polymyxin B which selectively binds LPS was added 
along with exogenous LPS or TNF. Heating rhuTNF-alpha to 100°C for 5 to 
15 minutes destroys the TNF induced neutrophil adhesion activity (Shalaby 
et al., 1987) and also abolishes its effects on the MPO-HgOg-halide 
activity (Klebanoff et al., 1986). Exogenous LPS (100 ng/ml) does not 
duplicate the rhuTNF-alpha effects on MPO^HgOg-halide activity even in 
the presence of unopsonized zymosan. In addition, LPS has no effect on 
the p815y target ADCC assay in the 5ng to 5 ug/ml concentration range 
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(Perussia et al., 1987). LPS does stimulate an increase in neutrophil 
ADCC of chicken red blood cells (CRBC), however, polymyxin B (10 ug/ml) 
inhibits this increase, yet polymyxin B has no effect on rhuTNF-beta-
mediated enhancement (Shalaby et al., 1985) or rhuTNF-beta induced 
increase in ADCC activity (Perussia et al., 1987). Polymyxin B (1 or 10 
ug/ml) has no direct effect on the adherence assay (Shalaby et al., 1987) 
nor does it effect rhuTNF-alpha dependent neutrophil MPO^HgOg-halide 
activity (Klebanoff et al., 1986) 
Anti-TNF monoclonal antibodies were used to determine the specificity 
of TNF induced enhancement of neutrophil activity. Random migration was 
not inhibited by TNF-alpha when monoclonal antibodies to TNF-alpha were 
included in the assay. The lack of random migration inhibition was not 
due to a direct effect of the antibody on the neutrophil (Shalaby et al., 
1987). Preincubation of rhuTNF-alpha with anti-TNF monoclonal antibodies 
totally inhibited TNF-stimulated adherence. Addition of the antibodies 5 
or 15 minutes after rhuTNF-alpha resulted in progressively less 
inhibition of adherence. In addition, mAbs to TNF inhibited the rhuTNF-
alpha induced MP0-H202-halide activity and the rhuTNF-beta-mediated 
increase in ADCC activity (Shalaby et al., 1985; Perussia et al., 1987). 
Little work has been done with TNF in vivo that did not involve 
looking for a direct cytotoxic effect of TNF on solid tumors. But it is 
known that intradermal injection of TNF into human beings results in a 
lesion that resembles a delayed skin test and TNF injection in murine 
skin results in neutrophil accumulation at the site of injection and 
erythema (Ruddle, 1987). 
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Table 3. Influence of recombinant TNF-alpha on neutrophil function 
in vivo 
Increases: 
'^Expression of iCSb 
fVdherence 
Disruption of endothelial cell 
monolayers 
^Superoxide anion production 
Phagocytic activity 
(TNF-alpha or -beta) 
'^Lysozynie release in response to 
. stimulus 
MPO-HgOg-halide activity 
^Cytotoxicity (ADCC) 
(TNF-alpha or -beta) 
Decreases: 
^Proliferation of endothelial cells 
in culture 
Unaffected: 
^Sxpresson of FcR by TNF-beta 
(Gamble et al., 1985; 
Shalaby et al., 1987) 
(Gamble et al., 1985) 
(Shalaby et al., 1987) 
(Shalaby et al., 1987) 
(Klebanoff et al., 1986; 
Shalaby et al., 1985) 
(Klebanoff et al., 1986) 
(Klebanoff et al., 1987) 
(Shalaby et al., 1985; 
Perussia et al., 1987) 
(Shalaby et al., 1987) 
(Perussia et al., 1987) 
(superscripts indicate neutrophils isolated from (h)humans treated 
with TNF-alpha or -beta from the same species) 
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INTERFERONS 
Interferon (IFN) was originally described as a protein mediator 
released from virus-infected cells which prevented viral replication in a 
target cell (Friedman and Vogel, 1983). It was soon realized that 
antiviral activity was due to a heterogeneous family of proteins which 
could be divided into two types of interferon. Type I, originally 
referred to as viral IFN, included both IFN-alpha and -beta that were 
produced by a variety of cells in response to virus infections but were 
first described as products of leukocytes and fibroblasts, respectively. 
Sequence determinations of cloned cDNAs have revealed more than a dozen 
members of the huIFN-alpha gene family and at least one and possibly two 
for huIFN-beta. Type II interferon, also called immune interferon or 
IFN-gamma, is induced by specific antigens, mitogens, or other stimuli 
and is the predominant form produced by stimulated lymphocytes. It has 
been realized that the interferons can be produced in response to not 
only viruses, but to cells infected with facultative intracellular 
bacteria and other bacterial antigens by a variety of cell types (Nakane 
and Minagawa, 1983; Stefanos et al., 1985; Weigent, Baron, and Stanton, 
1983). Interferon alone is not viricidal or bactericidal but plays an 
immunoregulatory role, affecting the microbicidal and cytocidal functions 
of both lymphoid and myeloid cells (Friedman and Vogel, 1983). 
Interferon gamma shares several characteristic activities with IFN-
alpha and -beta, but both IFN-alpha and -beta have greater antiviral 
activity than IFN-gamma (Friedman and Vogel, 1983). Interferon-gamma has 
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been reported to have a greater ability to inhibit proliferative and 
differentiation of hematopoietic precursor cells, than either alpha or 
beta (Broxmeyer et al., 1983). It has since been shown, however, that 
even the most purified preparations of IFN-gamma were contaminated with 
lymphotoxins (Stone-Wolff et al., 1984). Recombinant IFN-gamma without 
lymphotoxin exerts only a minimal inhibition of colony formation even at 
doses up to 1000 U/ml (Friedman and Vogel, 1983). Like IL-1, 
identification of the specific functions of IFN-gamma had to await 
cloning and production of a single protein. In addition to differences 
in biological activity and the stimuli that induce the production of IFN-
gamma, this type of interferon can be distinguished from IFN-alpha and 
-beta in several other ways. Interferon-gamma is of higher Mr (20-
25,000), is acid-labile (pH 2.0), in man is sensitive to 56°C, and is the 
product of only one gene that codes for a glycosylated protein (review; 
Trinchieri and Perussia, 1985). Recently, antigenic differences between 
the three forms of IFN have been detected by monoclonal neutralizing 
antibodies. 
Interferons exert their actions by binding to membrane receptors 
(Trinchieri and Perussia, 1985; Zoon, Zur Nedden and Arnheiter, 1986). 
At 37°C human IFN bound to its receptor and was internalized and 
ultimately degraded (Zoon et al., 1983; Zoon, Arnheiter, and Fizgerald, 
1985), an event often referred to as down-regulation of receptors. 
Interferon-alpha and -beta share a receptor which is different from the 
receptor for IFN-gamma (Branca and Baglioni, 1981), although one report 
indicates that IFN-gamma treatment of cells induces down-regulation of 
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IFN-alpha/beta receptors (Zoon and Arnheiter/ 1984). The number of IFN 
receptors per cell varies, but is generally less than 5000 (Zoon, Zur 
Nedden, and Arnheiter, 1986). The affinity of IFN for its receptor is 
very high, the apparent dissociation constants (Kd) are on the order of 
ICT^O lQ-11 A strong synergy has been described between IFN-gamma 
and -alpha/-beta in inducing antiviral activity (Fleischmann et al., 
1979), suggesting that the molecular events leading to this biolgical 
response may not be completely identical. 
The binding of interferons to specific receptors on the surface of 
mature neutrophils activates various aspects of neutrophil function. 
Recombinant huIFN-gamma increased the phagocytic activity of mature human 
neutrophils; 10 or 100 U/10® neutrophils resulted in increased 
phagocytosis of 1.5 um latex beads as detected by flow cytometry (Shalaby 
et al., 1985). Approximately 82% of nonactivated neutrophils can 
phagocytose and kill Candida albicans but these activities decrease in 
vitro over an 18 hour incubation to 43% (Perussia et al., 1987). 
Addition of rhuIFN-gamma did not enhance but maintained these activities 
at 82%. Neutrophil fungicidal activity and C3-opsonized zymosan 
stimulated phagocytosis were also maintained after an 18 hour incubation 
in the presence of rhuIFN-gamma. 
Recombinant huIFN-gamma increased the cytotoxic activity of the 
mature neutrophil. There was an increased percentage of ^^Cr-release in 
a four hour ADCC assay (optimal effector to target ratio 50:1, suboptimal 
ratio 5,10,25:1) against ^^Cr-labeled CRBC following a one hour 
pretreatment of neutrophils at 1-100 U/ml of huIFN-gamma (Basham, Smith, 
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and Merigan, 1984). Shalaby et al. (1985) found similar enhancement 
using slightly different assay conditions; effector to target ratio of 
4:1 and after one hour of pretreatment with lower doses of rhuIFN-gamma 
(0.01 to 1.0 U/ml). Apparently, higher doses also increased the 
neutrophil cytotoxic activity against CRBC but not in a dose-dependent 
manner (10^ to lo'^ U/ml) (Basham, Smith, and Merigan, 1984). In a three 
hour ADCC assay against ^^Cr-labeled p815y both biochemically pure and 
rhuIFN-gamma (200 U/ml maximal) increased human PMN cytotoxic activity 
(Perussia et al., 1987). The neutrophils were pretreated with rhuIFN-
gamma for varying times up to 48 hours prior to addition to the assay. 
Activity was increased after 4 hours and maximal after 18 hours, activity 
continued for 24 to 48 hours. The enhancement of neutrophil ADCC 
activity after 18 hours was not due to induction of INF since antibodies 
to TNF, which completely blocked the TNF-mediated enhancement of ADCC, 
had no effect on the ability of IFN-gamma to enhance the ADCC activity. 
Recombinant or natural huIFN-alpha and -beta at doses up to 1000 U/ml did 
not induce any enhancement of neutrophil ADCC against p815y target cells 
(Perussia et al., 1987). Higher doses of rhuIFN-alpha^ or -beta (500 
U/ml) have been reported to increase neutrophil ADCC activity towards 
CRBC targets to approximately the same extent as rhuIFN-gamma (Basham, 
Smith, and Merigan, 1984). These conflicting results might be explained 
by the different cells chosen as targets, which may vary in their 
abilities to be lysed by the neutrophil. 
The enhancement by rhuIFN-gamma of neutrophil ADCC has been proposed 
in part to be dependent on an IFN-induced expression of high-affinity 
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receptors (FcR^^g^) for monomeric IgG (Trinchieri and Perussia, 1985; 
Perussia et al., 1987; Shen et al., 1987). Normally, neutrophils do not 
express FcR^^g^ receptors but, as a process of differentiation, they 
acquire low-affinity (PcR^g^) receptors that bind aggregated IgG. 
Recombinant huIFN-gamma induced or enhanced the expression of high-
affinity Fc receptors on mature neutrophils and this correlated with the 
enhancement of ADCC activity (Perussia et al., 1987; Shen et al., 1987). 
This increase was dependent on neutrophil de novo synthesis of RNA and 
protein, determined by use of inhibitors of these cellular processes 
(Trinchieri and Perussia, 1985). The fact that rhulFN-alpha did not 
increase the ADCC activity against the p815y targets or the FcR^^^^, or 
high expression supported this conclusion (Perussia et al., 1987). 
However, these findings are in direct conflict with the reported 
enhancement of ADCC activity against CRBC after rhuIFN-alpha treatment of 
human neutrophils (Basham, Smith, and Merigan; 1984). A recent report by 
Perussia et al., (1987) emphasizes the expression of ^ cR^^^^ is not 
absolutely required, but plays a part in the enhanced ADCC activity. 
Neither rhuIFN-alpha nor rhuIFN-gamma affected CR3 density on the 
neutrophil surface over a treatment period varying from 3 to 18 hours 
(Perussia et al., 1987). This receptor, as previously stated, plays a 
part in neutrophil adherence and adherence-related activities. Two 
adherence related functions, phagocytosis and ADCC, were enhanced by the 
addition of rhuIFN-gamma, despite the apparent lack of increase in CR3 
expression (Perussia et al., 1987). These findings suggest that without 
overt deficiencies in CR3 expression, adherence-related activities can be 
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enhanced via other cellular processes. 
As mentioned previously^ E. coli LPS is a contaminant of the 
recombinant products. Addition of exogenous E. coli LPS to a final 
concentration of 50 ng/ml stimulated neutrophil phagocytosis of latex 
beads 3-fold, and enhanced the ADCC activity against ^^Cr-labeled CRBCs 
(Shalaby et al., 1985). A LPS concentration of 50 ng/ml was probably in 
excess of the contaminating concentration in the assays, which has been 
reported to be < 5 ng/ml after dilution. Others have reported no 
enhancement of ADCC against CRBC by LPS 0.1 to 100 ng/ml (Shen et al., 
1987). Polymyxin B addition, similar to the TNF experiments, blocked the 
LPS-induced but not cytokine-induced activity in both assays. Addition 
of a mixture of two monoclonal antibodies that recognize IFN-gamma, but 
not an irrelevant 11-2 monoclonal antibody, completely blocked the IFN-
gamma-induced enhancement of ADCC (10~^ neutralizing U/ml). 
Treatment of human neutrophils with a combination of rhuIFN-gamma and 
natural huTNF-beta exceeded activation induced by either agent alone. 
TNF-beta (10 U) plus IFN-gamma (1 U) enhanced phagocytosis of latex beads 
maximally at these combination doses, at higher concentrations of IFN-
gamma no further increase was noted (Shalaby et al., 1985). In addition 
TNF-beta (0.1 or 1 U/ml) plus IFN-gamma (1 CJ/ml) increased the ADCC 
activity to a greater extent than either cytokine alone. The ADCC 
activity against p815y targets was increased after an 18 hour 
pretreatment with rIFN-gamma and to an even greater extent if during the 
three hour assay rhuGM-CSF, LT or rTNF-alpha was added (alone these 
cytokines could minimally enhance ADCC) (Perussia et al., 1987). 
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Recombinant IFNs from other species have been examined to determine 
the specific effects on neutrophil function. Although recombinant murine 
IFN-gamma (rmuIFN-gamma) is available, very little work has been reported 
concerning its effect on murine neutrophil function. One report 
indicated that rmuIFN-gamma did not significantly enhance murine 
peritoneal neutrophil fungicidal activity against C. albicans but it did 
increase activity against Blastomyces dermatitidis (Morrison et al., 
1987). Neutrophil fungicidal activity against phagocytosable C. albicans 
was significantly higher (71.3 +17.4%) than against nonphagocytosable 
Blastomyces dermatitidis (extracellular killing). It was interesting, 
therefore, that a one hour pretreatment of neutrophils with rmuIFN-gamma 
(3 X 10"^ to 3 X 10^ U/ml) increased the fungicidal activity against B. 
dermatitidis. Maximal fungicidal activity against B. dermatitidis 
resulted in only 21% killing even at àn elevated concentration of rmuIFN-
gamma, 3 X 10^ U/ml. Exogenous LPS at levels corresponding to those in 
the recombinant product preparations did not enhance neutrophil 
fungicidal activity. Pretreatment of the IFN with rabbit anti-IFN 
antiserum before addition to the neutrophils eliminated the enhancement 
of fungicidal activity by effective doses of IFN. 
Peripheral blood neutrophils from cattle have also been treated with 
a recombinant bovine IFN-gamma (rboIFN-gamma) preparaton in vitro. 
Recombinant boIFN-gamma (50 U/ml) pretreatment for as little as five 
minutes or for longer time periods resulted in decreased random migration 
(Steinbeck, Roth, and Kaeberle, 1986; Bielfeldt Ohmann and Babiuk, 1986; 
Steinbeck and Roth, 1987) and decreased directed migration under agarose. 
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the decreases induced by higher concentrations of interferon were not 
linear (1 to 10^ U/ml) (Bielfeldt Ohmann and Babiuk, 1986). The rboIFN-
gamma itself was not chemotactic. After a 2.5 hour pretreatrnent with 
rboIFN-gamma/ there was no enhancement of superoxide anion production by 
the neutrophils in the cytochrome c assay in the presence of C3-opsonized 
zymosan (Steinbeck/ Roth, and Kaeberle, 1986; Bielfeldt Ohmann and 
Babiuk/ 1986). This was also true for neutrophils that were washed free 
of IFN before being added to the cytochrome c assay (Bielfeldt Ohmann and 
Babiuk/ 1986). These authors found that at a concentration of 1 x 10^ 
U/ml/ rboIFN-gamma actually inhibited the production of superoxide anion. 
Recombinant boIPN-gamma (50 U/ml) after a 2.5 hour pretreatment enhanced 
neutrophil ADCC activity in a two-hour ^^Cr-labeled CRBC (10:1) target 
assay (Steinbeck/ Roth/ and Kaeberle/ 1986; Steinbeck and Roth/ 1987). 
Interestingly/ the neutrophil antibody-independent lysis of the CRBC 
targets was also enhanced after pretreatment with rboIFN-gamma. Both the 
inhibition of migration and the enhancement of AINC required RNA and 
protein synthesis as determined by the use of inhibitors (alpha-amanitin 
(RNA) or puromycin or cycloheximide (protein)) of these metabolic events 
(Steinbeck/ Roth/ and Kaeberle/ 1986; Steinbeck and Roth/ 1987). The 
ADCC enhancement was not affected by these inhibitors. The enhancement of 
AINC was also dependent on arachidonic acid metabolism as determined by 
the use of two inhibitors of the lipoxygenase enzyme (Steinbeck and Roth/ 
1987). 
The neutrophils isolated from cattle immunosuppressed by 
intramuscular dexamethasone administration (0.04 mg/kg body wt) generally 
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have impaired functions. The pretreatment of these neutrophils in vitro 
with rboIFN-gamma (50 U/ml) resulted in the restoration of both random 
migration and ADCC activities to control values. Recombinant boIFN-gamma 
pretreatment of these neutrophils did not enhance the AINC activity, 
other activities were not evaluated. Immunosuppressed animals are more 
susceptible to microbial infections, and rboIFN-gamma may be a useful 
immunomodulator to reverse the effects of immunosuppression on neutrophil 
function. 
Both random migration and migration directed towards zymosan 
activated serum components were inhibited after 30 or 60 minutes of 
pretreatment with rboIFN-alpha (5 x 10^"^ U/ml) (Bielfeldt-Ohmann and 
Babiuk/ 1984; Bielfeldt Ohmann and Babiuk, 1986). Recombinant boIFN-
gamma inhibited directed and randan migration to a greater extent than 
rboIFN-alpha^ at any of the concentrations tested (Bielfeldt Ohmann and 
Babiuk; 1986). Recombinant boIFN-alpha^ (1000 U/ml) pretreatment for 30 
minutes enhanced bovine neutrophil bacterial uptake (phagocytosis) of 
antiserum-opsonized Staphylococcus aureus or E. coli (1:1) after three to 
four hours at 37°C (Bielfeldt-Ohmann and Babiuk, 1984). At lower doses 
of IFN the phagocytosis values were zero and at higher doses values were 
lower than at the optimal 1000 U/ml dose. Like rboIFN-gamma, rboIFN-
alpha (3000 U/ml maximal) did not affect superoxide anion production 
(Bielfeldt-Ohmann and Babiuk, 1984; Bielfeldt Ohmann and Babiuk, 1986) 
and was inhibitory at higher concentrations under the same assay 
conditions. Hydrogen peroxide production within 30 minutes of treatment 
was maximally enhanced by 3000 U/ml of rboIFN-alpha (Bielfeldt-Ohmann and 
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Babiuk/ 1984). Pretreatment of greater than one hour resulted in the 
loss of consistent effects on hydrogen peroxide production, which might 
be a result of a toxic effect of hydrogen peroxide on the neutrophil. 
Since the production of HgOg is directly dependent on the initial 
synthesis of superoxide anion, it can only be concluded that the assays 
vary in their sensitivity of detection. Lysozyme activity, which is not 
measurable in neutrophils from adult cattle, is present in neutrophils 
isolated from young cattle (10 days to 6 weeks of age). Treatment of 
neutrophils from young cattle for four hours with rboIFN-alpha (15 x 10^" 
5 
U/ml) decreased the presence of this enzyme (Bielfeldt Ohmann and 
Babiuk, 1986). This IFN over the same concentration range had no effect 
on the beta-glucuronidase activity of the neutrophils. One 
interpretation of these results might be that lysozyme expression is 
regulated by the environment of the bone marrow and this environment for 
whatever reason changes with the age of the cattle. 
Bielfeldt Ohmann and Babiuk (1986) reported that i.v. or i.m. 
administration of 10^ or 10® U of rboIFN-alpha or -gamma altered 
neutrophil functions as measured in vitro. Depending on the doseage, 
IFN, route, or time after administration, the neutrophils from treated 
cattle had decreased random and directed migration and stimulated 
superoxide anion production. In addition, an increase in circulating 
neutrophil numbers occurred within the first 24 hours after IFN 
administration. The time that it took to see an effect and the effect 
itself was not dose-dependent and varied considerably. This can probably 
be explained by the fact that the cytokines can bind to numerous cell 
# 
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types and their effects would be dependent on the cells contacted in the 
local area of administration. 
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Table 4. Influence of recombinant IFN-gamma on neutrophil function 
in vitro 
Increases: 
'^Superoxide anion production 
, after in vivo admin, to cattle 
'""phagocytic activity 
["Fungicidal activity 
Expression of 
'^''^Cytotoxicity (ADCC) 
^Cytotoxicity (AINC) 
^Cytotoxicity (ADCC) (neutrophils 
from immunosuppressed cattle) 
Decreases: 
'^Random migration 
^Directed migration 
Random migration (neutrophil 
. from immuosuppresssed cattle) 
Lysozyme activity, of neutrophils 
from young calves 
(Bielfeldt Ohmann and Babiuk, 1986) 
(Shalaby et al., 1985; 
Morrison et al., 1987) 
(Morrison et al., 1987) 
(Trinchieri and Perussia, 1985; 
Perussia et al., 1987) 
(Basham et al., 1984; Shalaby et 
al., 1985; Steinbeck, Roth, and 
Kaeberle, 1986; Bielfeldt Ohmann 
and Babiuk, 1986; Perussia et al., 
1987; Steinbeck and Roth, 1987) 
(Steinbeck, Roth, and Kaeberle, 
1986; Steinbeck and Roth, 1987; 
Morrison et al., 1987) 
(Steinbeck and Roth, 1987) 
(Steinbeck, Roth, and Kaeberle, 
1986; Steinbeck and Roth, 1987; 
Bielfeldt Ohmann and Babiuk, 1986) 
(Bielfeldt Ohmann and Babiuk, 1986) 
(Steinbeck and Roth, 1987) 
(Bielfeldt Ohmann and Babiuk, 1986) 
Unaffected: 
. ^Expression of CR3 (Perussia et al., 1987) 
' Superoxide anion production (Perussia et al., 1987; Bielfeldt 
Ohmann and Babiuk, 1986; Steinbeck, 
Roth, and Kaeberle, 1986) 
.Phagocytic activity (Steinbeck, Roth, and Kaeberle, 1986) 
Phagocytic activity was main- (Perussia et al., 1987) 
tained after 18 hours in culture 
(superscripts indicate neutrophils isolate from (h)human, (b)bovine, 
and (m)murine) treated IFN-gamma from the same species) 
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Table 5. Influences of recombinant IFN-alpha on neutrophil function 
in vivo 
Increases: 
'^Neutrophil numbers in peripheral 
blood after in vivo admin. 
, to cattle 
Superoxide anion production after 
b i" vivo admin, to cattle 
.Phagocytic activity 
.Hydrogen peroxide production 
Cytotoxicity (ADCC) against CRBC 
targets (IFN-alpha and -beta) 
(Bielfeldt Ohmann and Babiuk/ 1985) 
(Bielfeldt Ohmann and Babiuk/ 1985) 
(Bielfeldt-Ohmann and Babiuk, 1984) 
(Bielfeldt-Ohmann and Babiuk/ 1984) 
(Basham et al., 1984) 
Decreases: 
^Random migration 
'^Directed migration 
'^Lysozyme activity in neutrophils 
from young calves 
(Bielfeldt-Ohmann and Babiuk/ 1984; 
Bielfeldt Ohmann and Babiuk/ 1986) 
(Bielfeldt-Ohmann and Babiuk, 1984; 
Bielfeldt Ohmann and Babiuk/ 1986) 
(Bielfeldt-Ohmann and Babiuk, 1984) 
Unaffected: 
^Expression of CR3 
'^Superoxide anion production 
in response to stimulus 
^Beta-glucuronidase activity in 
neutrophils from young calves 
'^Expression of FcR^^g^ 
^Cytotoxicity (ADCC) for p815y 
targets (IFN-alpha or -beta) 
(superscripts indicate neutrophils 
(b)bovine treated with IFN-alpha ; 
(Perussia et al./ 1987) 
(Perussia et al./ 1987) 
(Bielfeldt-Ohmann and Babiuk/ 1984; 
Bielfeldt Ohmann and Babiuk/ 1986) 
(Bielfeldt-Ohmann and Babiuk/ 1984) 
(Perussia et al., 1987) 
(Perussia et al./ 1987) 
isolated from (h)human/ and 
the same species) 
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SUMMARY 
Interest in the use of recombinant cytokines for immunotherapy is 
increasing as more information becomes available on the influences of 
these products on effector cells (e.g., neutrophils) involved in the 
resistance of the host to disease. This review summarizes the 
information available on in vitro and in vivo activation of neutrophils 
by recombinant cytokines. The emerging theme is that various cytokines 
(colony-stimulating factors, tumor necrosis factors, interferons) have 
direct and often synergistic abilities to activate the neutrophil to have 
enhanced cytocidal activity towards microbial and cellular stimuli. 
Equally as important (although less well studied) cytokines have been 
shown in some cases to activate neutrophils isolated from 
immunosuppressed animals. These neutrophils have depressed function and 
influences of cytokines on these cells may be different from their 
influences on normal neutrophils. We chose to discuss only recombinant 
cytokine data in this review because of the confusion caused by protein 
contaminants which may be present within biochemically purified 
preparations. 
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ABSTRACT 
The effect of recombinant bovine gamma-interferon (rboIFN-gamma) on 
neutrophil functions was investigated and compared to the effects of an 
unpurified lymphokine preparation. Incubation of purified bovine 
neutrophils with rboIFN-gamma or antigen-induced lymphokine for 2.5 hours 
at 37°C resulted in impairment of the ability of neutrophils to migrate 
under agarose/ and an enhancement of their ability to mediate antibody-
dependent and antibody-independent cell-mediated cytotoxicity against 
chicken erythrocytes (CRBC). Neither the lymphokine preparation nor the 
rboIFN-gamma had any influence on Staphylococcus aureus ingestion, or 
iodination by neutrophils. The lymphokine preparation enhanced 
cytochrome C reduction by neutrophils and was weakly chemotactic, whereas 
the rboIFN-gamma had neither of these effects. Only five minutes of 
rboIFN-gamma preincubation with neutrophils were needed to trigger 
protein synthesis by the neutrophils resulting in inhibition of random 
migration. Therefore/ recombinant gamma-interferon acts as a neutrophil 
migration inhibition factor and a neutrophil activation factor resulting 
in enhanced neutrophil mediated antibody-dependent and -independent cell-
mediated cytotoxicity. Many, but not all/ of the in vitro effects of an 
unpurified lymphokine preparation on neutrophil function can be 
attributed to the gamma interferon contained in the lymphokine. 
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INTRODUCTION 
We have previously reported that an antigen-induced bovine 
lymphokine, containing measurable interferon activity/ enhanced 
neutrophil Staphylococcus aureus ingestion, NBT reduction, and antibody-
dependent cell-mediated cytotoxicity (ADCC), and impaired neutrophil 
migration under agarose (Lukacs, Roth, and Kaeberle, 1985). We also 
reported the apparently novel finding that lymphokine treatment caused 
neutrophils to be cytotoxic for xenogeneic (but not allogeneic) 
erythrocytes in the absence of antibody (antibody-independent neutrophil 
cytotoxicity) (AINC) (Lukacs, Roth, and Kaeberle, 1985). The enhancement 
of AINC but not ADCC required a 2 hour period of preincubation and was 
dependent on RNA and protein synthesis by the neutrophil. 
In other experimentation we found that the administration of an 
interferon inducer (avridine) counteracted most of the effects of 
dexamethasone on neutrophil function (Roth and Kaeberle, 1985). 
Neutrophils were obtained from cattle given avridine 24 hours prior to 
receiving dexamethasone and the results were compared to neutrophils 
obtained from cattle given dexamethasone only. Neutrophils from avridine 
pre-treated cattle had enhanced S. aureus ingestion, oxidative 
metabolism, and ADCC and a reduction in random migration under agarose 
when compared to neutrophils from cattle treated with dexamethasone only. 
Since the avridine probably induced a variety of potential biologic 
response modifiers, it could not be assumed that the avridine effects 
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were due to interferon only. 
Both the lymphokine preparation in vitro and avridine administration 
in vivo enhanced bovine neutrophil activity. The lymphokine contained 
gamma interferon, and avridine is reported to induce interferon in vivo, 
therefore, it was of interest to determine the effects of purified gamma 
interferon on neutrophil function. Recombinant DNA technology has made 
available several different interferon molecules for use in research. 
Other investigators have used recombinant interferons (human IFN-alpha, 
beta, gamma and bovine IFN-alpha ^  & g) and have shown that these 
interferons are biologically active in various assays (Basham, Smith, and 
Merigan, 1984; Bielfeldt-Ohmann and Babiuk, 1984). In recent reports, 
recombinant interferon has been shown to enhance human neutrophil ADCC 
(Basham, Smith, and Merigan, 1984) and neutrophil phagocytosis 
(Bielfeldt-Ohmann and Babiuk, 1984). A rboIFN-alpha also inhibited 
random migration of neutrophils under agarose (Bielfeldt-Ohmann and 
Babiuk, 1984). Our previous work and work of others lead us to 
investigate the effect of recombinant bovine gamma-interferon (rboIFN-
gamma) on neutrophil function and to compare it to the effects of 
unpurified antigen-induced lymphokine. 
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MATERIALS AND METHODS 
Neutrophil preparation. Neutrophils were separated as previously 
described (Lukacs, Roth/ and Kaeberle, 1985). Briefly/ peripheral blood 
was collected from healthy cattle into acid-citrate-dextrose solution/ 
centrifuged/ and the plasma and buffy coat layer were discarded. The 
packed erythrocytes were lysed by brief exposure to hypotonic conditions 
and the remaining cells/ which generally consisted of greater than 90% 
polymorphonuclear leukocytes (PMNS)/ were washed in 0.015 M phosphate 
buffered saline solution (BBSS) (pH 7.2) and suspended in Medium 199, 
containing 25 mM HEPES buffer/ to a concentration of 1.0 X 10® PMN/ml. 
Lymphokine and rboIFN-gamma. The lymphokine was induced in vitro by 
stimulating purified mononuclear cells obtained from cattle which had 
been infected with infectious bovine rhinotracheitis (IBR) virus 
(herpesviridae) with heat-inactivated IBR virus. This method has been 
descibed elsewhere in detail (Lukacs/ Roth/ and Kaeberle/ 1985). The 
bovine rboIFN-gamma was supplied by Genentech Inc./ South San Francisco, 
CA (Lot number 2433/21,33/95) with a specific activity of _> X 10® 
U/mg (MDBK-VSV). 
Treatment of PMN with lymphokine or rboIFN-gamma. Three hundred 
Q 
microliters of a 1.0 X 10 /ml suspension of PMN were incubated with 300 
ul of different dilutions of rboIFN-gamma or lymphokine (diluted in 
Medium 199 with HEPES) for 2.5 hours at 37°C. The PMNs were then used in 
the functional assays without washing. Control PMN preparations were 
incubated with Medium 199 with HEPES. 
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Evaluation of neutrophil function. The procedure for evaluation of 
random migration under agarose, chemotaxis, S. aureus ingestion, 
iodination, ADCC and AINC have previously been described (Lukacs, Roth, 
and Kaeberle, 1985) 
Cytochrome c reduction. The standard reaction mixture contained 
0.075 ml cytochrome c (538 uM in Hanks balanced salt solution without 
phenol red (HBSS), 0.025 ml PMNs (5.0 X 10^/ml), 0.025 ml opsonized 
zymosan preparation (5 mg/ml HBSS), and 0.05 ml of HBSS. The zymosan 
suspension was replaced with HBSS for the determination of resting 
cytochrome c reduction. All reactants were added to wells in a 96 well 
millititer filtration plate (SV, Millipore Corp., Bedford, MA) which had 
been pre-wetted with 0.5% bovine serum albumin. The reaction was started 
by the addition of PMNs and the plate was incubated at 37°C for 30 
minutes with constant agitation. The reaction was stopped by vacuum 
filtration and collection of the filtrate in a flat bottom microtiter 
plate (millipore vacuum holder, Millipore Corp., Bedford, MA). The PMNs 
trapped on the filter were washed twice by filtration with 0.05 ml of 
HBSS and those filtrates were collected in the same microtiter plate. 
The filtrate optical density (CD) at 550 nm was determined. The results 
were expressed as OD/1.25 X 10® PMNs/30 minutes reaction time. 
Inhibitor studies. Alpha-amanitin and puromycin (Sigma Chemical Co., 
St. Louis, Mo.) were used to inhibit RNA and protein synthesis 
respectively by PMNs during the incubation of PMNs with rboIFN-gamma. 
PMNs were first preincubated with alpha-amanitin (50 ug/ml) or puromycin 
(10 ug/ml) or both for 30 min at 37°C; rboIFN-gamma containing the same 
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concentration of inhibitor(s) was then added to the PMNs (without 
washing) and the incubation continued for 2.5 hours. 
Incorporation of L-[ Sjmethionine into acid-insoluble proteins. 
Purified PMNs (5.0 X 10®) were plated in 16 mm tissue culture dishes (24 
well Costar 3524» Costar, Cambridge MA) in 150 ul of RPMI 1640 medium 
lacking methionine but supplemented with 0.1% (w/v) bovine serum albumin 
in an atmosphere of 5% air at 37°C either in the presence or 
absence of cycloheximide (10 ug/ml) or puromycin (10 ug/ml) (protein 
y 
synthesis inhibitors). After 30 minutes the cultures received 150 ul of 
medium containing 120 uCi of L-[^^S]methionine with or without lymphokine 
(1:5) and + inhibitor. The cells were resuspended by gentle pipetting 
2.5 hours later, washed twice by centrifugation in cold tris-buffered 
saline, and solubilized in 100 ul of lysis buffer containing ImM 
phenylmethylsulphonyl fluoride and ImM aprotinin. An equal volume of 
cold 20% trichloroacetic acid (TCA) was added, and the resulting 
precipitate was collected on glass fiber filters (GC filters Whatman, 
Inc., Clifton, NJ). The filters were washed with 10% TCA, dried, and 
counted in a toluene-based scintillation fluid (Liquifluor, New England 
Nuclear, Boston, MA) in a liquid scintillation counter (Packard 
Instrument Co., Inc., Downers Grove, IL). 
Data analysis. Statistical significance was determined using a 
Dunnett's multiple comparison test of two means (untreated and 
treatment), this procedure uses conservative degrees of freedom in 
determining the level of significance. The individual PMN preparations 
were used as blocking factors in the analysis of variance in order to 
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remove the animal to animal variability from statistical consideration of 
the treatment effect (i.e., the value for a treated PMN preparation was 
compared to the value from an aliquot of that same PMN preparation that 
was untreated). 
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RESULTS 
The results in Table 1 indicate that both lymphokine and rboIFN-gamtna 
treatment of PMNs enhanced the percentage of ^^Cr release from the CRBCs 
as compared to the untreated neutrophils incubated in medium alone. The 
elevated ^^Cr release from the CRBCs was evident in the presence (ADCC) 
and abscence of antibody (AINC). In both assays the rboIFN-gamma 
activity decreased in a concentration dependent manner, showing 
measurable activity out to a dilution of 5 X 10"^^ gm/ml. Included in 
Table 1 are the results of the random migration under agarose assay. 
Both the rbolFN-gamma and lymphokine treatments (preincubation 2.5 hrs) 
inhibited PMN random migration with the rboIFN-gamma demonstrating 
concentration dependence. 
The results for S. aureus ingestion, iodination, and unstimulated 
cytochrome c reduction in Table 2 were similar in the untreated and 
treated neutrophils. The lymphokine treatment did cause a small but 
significant enhancement of cytochrome c reduction by zymosan-stimulated 
neutrophils. The rboIFN-gamma did not have this same effect. 
Table 1. IBR virus-induced lymphokine and recombinant bovine gamma-interferon effects on bovine 
neutrophil cytotoxicity in the presence and absence of antibody and on neutrophil random 
migration 
Pretreatment of Neutrophils 
Medium 199 IBR virus- Bovine gamma interferon (gm/ml) 
induced _ 
ASSAY lymphokine 5x10 5x10" 5xlO~ 5x10 
Antibody-independent 18.7+3.6 41.1+4.3^ 31.9+3.8^ 32.0+4.5^ 27.4+3.9^ 22.0+3.2 
neutrophil cytotoxicity 
(% release of Cr) , 
Antibody-dependent 54.4+2.8 64.0+2.2® 62.6+2.1® 61.7+2.8® 59.3+2.7 58.3+2.7 
neutrophil cytotoxicity 
(% release of Cr) 
Migration un^er 21.9+2.1 8.8+1.7® 7.1+1.2® 8.9+1.2® 14.0+1.8® 18.7+2.3 
Agarose (mm ) 
®P < .01; 
< .05; the level of statistical significance for the difference between the indicated 
value and the corresponding value of neutrophils preincubated in Medium 199. Data expressed as 
the mean + SEM (n=15). 
Table 2. IBR virus-induced lymphokine and recombinant bovine gamma-interferon effects on 
bovine neutrophil functions 
Pretreatment of Neutrophils 
Medium 199 IBR virus- Bovine gamma interferon (gm/ml) 
ASSAY 
induced 
lymphokine 5x10"® 5x10"^ 5x10"^° 5xl0"ll 
S. aureus ingestion 
{%) n=19 
26.6+1.7 26.4+1.2 27.3+1.3 27.6+1.5 25.8+1.4 26.1+1.7 
lodination n=18 
(nmole NaI/10 PMNs/hr) 
30.3+4.3 31.9+3.5 31.8+3.7 31.7+4.4 30.6+3.9 29.8+3.9 
Cytochrome c reduction 
(unstimulated) n=20 
(00/5x10 PMNs/30 min) 
O.ll+.Ol 0.11+.02 0.10+.01 0.10+.02 0.11+.02 O.ll+.Ol 
Cytochrome c reduction 
(stimulated) n=20 
(00/5x10 PMNs/30 min) 
0.38+.02 0.42+.02® 0.38+.01 0.37+.02 0.39+.02 0.36+.02 
^ < .01; the level of statistical significance for the difference 
between the indicated value and the corresponding vsLLue of neutrophils 
preincubated in Medium 199. 
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To evaluate the kinetics of rboIFN-gamma interaction with PMNs/ 
the PMNs were preincubated with 5 X 10~® gm/ml rboIFN-gamma at 37°C 
for 5/ 30/ or 150 minutes then washed to remove unbound rboIFN-gamma. 
Controls were incubated in medium for 150 minutes then washed. All 
cells were incubated for a total of 150 minutes (combination of before 
and after washing) before being added to the wells in the migration 
plates. The migration inhibition results for the 5, 30/ and 150 
minute time periods were 77.3+5.0/ 73.5+4.8/ and 67.3+_5.7 (mean SEM) 
(n=6) respectively/ expressed as a percentage of the value for control 
PMNs. Therefore, 5 minutes of exposure of neutrophils to rboIFN-gamma 
was all that was required to trigger migration inhibition. 
The need for RNA and protein synthesis for the rboIFN-gamma 
inhibition of neutrophil migration was investigated using alpha-
amanitin (50 ug/ml) and puromycin (10 ug/ml). At these concentrations 
the inhibitors did not affect cell viability as determined by trypan 
blue exclusion (> 95% viable). Inhibition of either RNA or protein 
synthesis partially blocked the effect of rboIFN-gamma on random 
migration (Table 3a). The combination of both RNA and protein 
synthesis inhibitors was capable of completely blocking the rboIFN-
gamma inhibition of PMN migration. 
The amount of L-[^^S]methionine incorporation into protein by PMNs 
was determined by TCA protein precipitation on glass fiber filters and 
liquid scintillation counting. Purified PMNs were cultured in the 
presence of RPMI 1640 medium containing 60 uCi of L-[^^S]methionine. 
Incorporation of L-[^^S]methionine was detectable in both untreated 
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and lymphokine-treated PMN fractions (Table 3b). The incorporation of 
radiolabel was inhibited >90% in both PMN fractions when either 
cycloheximide (10 ug/ml) or puromycin (10 ug/ml) were included during 
the 2.5 hour incubation. Incorporation of L-[ S]methionine was 
similar in rboIFN-ganuna-treated PMNS (data not shown). 
The chemotactic activities of various dilutions of lymphokine and 
rboIFN-gamma for PMNS are shown in Table 4. The undiluted lymphokine 
preparation was weakly chemotactic for neutrophils. It was not 
chemotactic at a dilution of 1:10. Recombinant IFN-gamma was not 
chemotactic for neutrophils over a concentration range of 1 X 10~° to 
10~^^ gm/ml. 
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Table 3a. Effect of inhibitors of protein and RNA synthesis on rbo-
IFN-ganuna migration inhibition activity for neutrophils 
Area of random migration (mm^) 
Pretreatment of PMNs^ PMNs + medium PMNs + IFN 
(lxlO~® gm/ml) 
Medium 199 44 
alpha-amanitin 40 
Puromycin 43 
alpha-amanitin + 40 
puromycin 
.9+9.5 18.0+3.7^ 
.3+8.4 33.1+6.7 
.3+10.5 38.4+8.4 
.7+9.5 40.1+9.2 
PMNs were preincubated with 50 ug/ml alpha-amanitin and/or 
10 ug/ml puromycin for 30 minutes at 37 C, and then for 2.5 hours in 
the presence or absence of IxlO" gm/ml rboIFN-gamma + inhibitor 
before being assayed. Results are the mean SEM (n=9) 
^P < .01; the level of statistical significance for the differ­
ence between the indicated value and the value for medium 199-treated 
neutrophils. 
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Table 3b. Effect of inhibitors of protein synthesis on L-[^^S]-
methionine incorporation into acid-precipitable proteins 
L-[^^S]methionine (cpm X 10^) 
Pretreatment of PMNs^ PMNs + RPMI 1640 PMNs + lyitiphokine 
RPMI 1640 
Cycloheximide (10 ug/ml) 
Puromycin (10 ug/ml) 
7.92 8.08 
0.62 0.69 
0.60 0.56 
^MNs (5 X 10 PMN) were pretreated by incubation in RPMI 1640 
medium + 10 ug/ml cycloheximide or 10 ug/ml puromycin for 30 minutes 
at 37°C/ and then for 2.5 hours in the presence of lymphokine or 
medium (+ inhibitors) containing a final concentration of 60 uCi of 
L-[ S]-methionine before being assayed. The values presented are 
from a single experiment (triplicate cultures); comparable results 
were obtained in subsequent experiments. 
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Table 4. The effects of rboIFN-gamma/ lymphokine, and zymosan 
activated serum on neutrophil chemotaxis under agarose 
Chemotactic factor Chemotactic index 
Zymosan activated serum 
1:2 1.46 +.03® 
IBR-virus induced lymphokine 
1:1 
1:10 1.03 +.03 
1.13 +.02& 
Bovine gamma interferon 
10"5 1.02 +.01 
10"; 1.06 +.01 
10~° 1.04 +.03 
icr= 1.02 +.03 
lOT^Y 0.92 +.02 
ICT^l +,02 
^ < .01; the level of statistical significance for the differ­
ence between the indicated value and the value for medium 199 as the 
control chemotactic factor. Data are expressed as mean + SEM (n=6). 
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DISCUSSION 
These data indicate that many but not all of the effects of the 
unpurified lymphokine preparation on neutrophils can be attributed to 
gamma interferon. Both the lymphokine preparation and rboIPN-gamma 
inhibited random migration and enhanced AINC and ADCC activity 
compared to the non-treated neutrophils (Table 1). The lymphokine, 
however/ enhanced the neutrophil oxidative metabolism and was 
chemotactic whereas the rboIFN-gamma did not have these effects. It 
is possible that other molecules within the lymphokine preparation are 
active either alone or in combination with gamma-interferon. Others 
have noted that a 'synergy' exists; the lymphokines work most 
effectively in combinations or in sequence rather than individually 
(Hamblin, 1985). The observed differences between the lymphokine 
preparation and the rboIFN-gamma could also be due to a difference in 
IFN-gamma concentration or to differences in the biologic activity of 
natural and recombinant gamma interferon. 
The rboIFN-gamma did activate the neutrophil to have enhanced 
cytotoxic activity in both the presence and absence of specific 
antibody. We have previously reported the enhancement of ADCC and 
AINC activity of neutrophils using antigen-induced lymphokine 
preparations (Lukacs, Roth, and Kaeberle, 1985). The lymphokine 
activated PMNs had enhanced AINC activity against heterologous 
erthyrocyte systems including chicken, turkey, and human, but not 
homologous bovine erythrocytes. The lymphokine itself was not 
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cytotoxic for the CRBCs (Lukacs, Roth/ and Kaeberle, 1985). In 
addition/ the cytotoxic activity was not due to increased phagocytosis 
by the neutrophil as neither lymphokine nor rboIFN-gamma treated 
neutrophils had enhanced phagocytic activity (Table 2). Basham et al. 
(1984) recently reported an enhancement of neutrophil ADCC using human 
rboIFN-gamma and CRBCs as target cells. Antibody-independent 
cytotoxic activity has previously been described for normal human 
peripheral blood neutrophils (Banerjee et al./ 1981; Ohara et al./ 
1983) toward rabbit erythrocytes (RRBC) in the prescence of gamma­
globulin depleted human serum (Banerjee et al./ 1981). In that system 
the AINC activity required, cell to cell contact and was specific for 
RRBCs. Chicken RBCs were not lysed when co-incubated with the RRBCs. 
The supernatant removed from the lysed RRBCs was not cytotoxic for 
fresh RRBC. This activity did not involve phagocytosis/ cytophilic 
antibody absorption to the surface/ nor the Forssman heterophile 
antigens (Banerjee et al./ 1981; Ohara et al./ 1983). Human 
peripheral blood granulocytes also are known to have the capacity to 
recognize and selectively destroy human tumor cells in vitro in the 
absence of antibody (Gerrard/ Cohen/ and Kaplan/ 1981; Chee et al./ 
1978). The lymphokine-induced enhancement of AINC by bovine PMNs 
required at least 2 hours of preincubation with lymphokine; and either 
RNA or protein synthesis inhibitors could prevent the lymphokine 
enhancement (Lukacs/ Roth/ and Kaeberle/ 1985). The enhancement of 
natural killer cell cytotoxicity by human leukocyte interferon also 
requires RNA and protein synthesis (Bishop and Schwartz/ 1982). RNA 
70 
and protein synthesis by the PMNs were not required for enhancemant of 
ADCC by bovine lymphokine. The AINC activity was inhibited by 
superoxide dismutase, catalase/ mannitol, azide, colchicine, and 
cytochalasin B; indicating that protein synthesis, oxidative 
metabolism, microfilament function, and microtubule function are 
important in the AINC activity (personal communication). 
We found that the rboIFN-gamma was not chemotactic for 
neutrophils, which was similar to the results found with human rlFN-
alphag (Farr et al., 1983). The undiluted lymphokine preparation, 
however, did possess weak chemotactic activity (Table 4). Neutrophil 
migration under agarose was markedly inhibited by rboIFN-gamma (Table 
1). The migration of bovine neutrophils was previously reported to be 
inhibited by bovine rboIFN-alpha^ (Bielfeldt-Ohmann and Babiuk, 1984) 
and by lymphokine (Lukacs, Roth, and Kaeberle, 1985). Our results 
indicate that only 5 minutes of preincubation in the presence of 
rboIFN-gamma was necessary to cause an inhibition of neutrophil random 
migration. Apostolov and Barker (1981) reported that cell membrane 
buoyant density results did not differ if mouse L cells were incubated 
in the continual presence of interferon or washed after 1 hour. They 
concluded that the initial interferon concentration determined the 
reaction of the cell and it was not a continual action of interferon. 
In addition, the continued presence of interferon on human amnion 
(WISH) cells was not required since the cells could be washed after 
overnight interferon treatment with no loss of antiviral activity 
(Blalock and Stanton, 1980). 
71 
The short 5 min preincubation with rboIFN-gamma apparently 
triggered protein synthesis by the neutrophils since both RNA and 
protein synthesis were necessary for optimal inhibition of migration 
by rboIFN-gamma. We have previously reported that neutrophils 
incubated with bovine lymphokine must be capable of protein synthesis 
in order to be fully activated in AINC (Lukacs, Roth, and Kaeberle, 
1985). In accordance with this data, a measurable amount of L-
C S]methionine was incorporated into newly synthesized protein in 
both untreated and lymphokine treated neutrophils (Table 3b). The 
incorporation was inhibited >90% by protein synthesis inhibitors, 
cycloheximide and puromycin. The incorporation of [ H]leucine, 
C^H]uridine (Granelli-Piperno, Vassalli, and Reich, 1979), and L-
35 S]methionine (Blowers, Jayson, and Jasani, 1985) into untreated and 
dexamethasone treated human peripheral blood neutrophils has been 
previously reported. 
In summary, the data presented here suggests a role for 
neutrophils as effector cells in T cell directed immunity (gamma 
interferon is produced by antigen-stimulated T cells). The inhibition 
of neutrophil migration by rboIFN-gamma may be important for retention 
of neutrophils at the site of interferon production. The rboIFN-gamma 
can also act as a neutrophil activation factor resulting in the 
enhancement of both AINC and ADCC activity. 
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ABSTRACT 
Bovine neutrophils were preincubated with recombinant bovine gamma 
interferon (rboIFN-gamma) and the molecular events leading to enhanced 
antibody-dependent (ADCC) and antibody-independent (AINC) neutrophil-
mediated cytotoxicity and impaired random migration under agarose were 
investigated. Addition of alpha-amanitin, puromycin, or cycloheximide 
(RNA and protein synthesis inhibitors) during preincubation and 
assaying prevented the rboIFN-gamma enhancement of AINC and inhibition 
of random migration, but did not prevent the ADCC enhancement. In 
addition, rboIFN-gamma treatment of neutrophils consistently increased 
the synthesis of a 60 and a 93-94 kilodalton (kD) protein after 60 
minutes but within 2 hours of incubation. Neutrophils purified from 
dexamethasone-treated cattle also had increased synthesis of a 60 kD 
protein, enhanced ADCC and inhibited migration following rboIFN-gamma 
treatment but did not have enhanced AINC. Dexamethasone has been 
shown to decrease the formation of arachidonic acid lipoxygenase 
products by bovine neutrophils. Addition of lipoxygenase inhibitors 
(NDGA and BW755C) to neutrophils from nondexamethasone-treated cattle 
following rboIFN-gamma preincubation (i.e., after protein synthesis 
had occurred) eliminated the enhancement of AINC. This suggests that 
dexamethasone does not affect the rboIFN-gamma induced protein 
synthesis required for migration inhibition or AINC enhancement, but 
acts to inhibit the production of arachidonic acid lipoxygenase 
products which are also required for the AINC activity. 
75 
We have concluded that the enhancement of the AINC activity and 
inhibition of random migration (but not the enhancement of ADCC) 
required both RNA and protein synthesis which resulted in the 
increased expression of at least one protein. Only the enhanced AINC 
activity required the generation of lipoxygenase products of 
arachidonic acid. 
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INTRODUCTION 
We have previously reported that after a 2.5 hour preincubation 
with rboIFN-gamma, bovine neutrophils had enhanced antibody-dependent 
(ADCC) and -independent (AINC) neutrophil-mediated cytotoxicity and 
impaired random migration (Lukacs/ Roth, and Kaeberle, 1985). The 
neutrophils did not show any consistent enhancement of oxidative 
metabolism# degranulation, or ingestion activities. Shalaby et al. 
(1985) have also reported human neutrophil ADCC enhancement and 
impaired random migration after a 2 hour preincubation with human 
rboIFN-gamma. 
We are interested in the potential use of rboIPN-gamma as an 
immunomodulator in immunosuppressed cattle. Intramuscular 
administration of dexamethasone to cattle (0.04 mg/kg body weight) has 
been reproducibly used to induce immunosuppression. This synthetic 
glucocorticoid reduces neutrophil oxidative metabolism, iodination, 
and antibody-dependent cell-mediated cytotoxicity and enhances 
neutrophil random migration (Roth and Kaeberle, 1985). Dexamethasone 
treatment of cattle also leads to a decrease in arachidonic acid 
release from bovine neutrophil membrane phospholipids after in vitro 
opsonized-zymosan stimulation (Webb and Roth, 1987). The arachidonic 
acid released is converted by the lipoxygenase pathway into two major 
products, leukotriene-B^ and 5-HETE. These products are necessary for 
optimal iodination and oxidative response by bovine neutrophils but 
are less important for random migration, ingestion, and ADCC (Webb and 
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Roth, 1987). We have previously reported the need for neutrophil 
protein synthesis for the inhibition of neutrophil random migration by 
rboIFN-gamma (Steinbeck, Roth, and Kaeberle, 1986). Enhancement of 
AINC by an antigen-induced lymphokine also required the bovine 
neutrophil to synthesize RNA and protein (Lukacs, Roth, and Kaeberle, 
1985). In contrast, the ADCC enhancement by lymphokine was not 
decreased by inhibitors of RNA and protein synthesis. This correlates 
well with the observation that enhancement of ADCC did not require any 
preincubation with lymphokine (Lukacs, Roth,and Kaeberle, 1986). 
Protein synthesis has been reported to be unnecessary for enhancement 
of bovine neutrophil ADCC by other researchers. Unpurified immune 
interferon enhanced neutrophil ADCC against chicken red blood cell 
(CRBC) and infectious bovine rhinotracheitis (IBR)-infected targets in 
the presence of protein synthesis inhibitors (Wardley, Babiuk, and 
Rouse, 1976). Monocyte factors also enhanced neutrophil ADCC against 
CRBC targets in the presence of inhibitors of protein synthesis (Frank 
and Roth, 1986). 
The purpose of the research reported here was to investigate the 
activity of rboIFN-gamma on neutrophils from normal and dexamethasone-
treated cattle and to determine the differential roles of RNA 
transcription, protein synthesis, and arachidonic acid metabolism in 
the rboIFN-gamma induced inhibition of random migration and 
enhancement of ADCC and AINC activities. 
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MATERIALS AND METHODS 
Animals. Twenty healthy, one to two-year-old Holstein steers were 
used in this study. Dexaraethasone (Azium, Sobering Corp, Kenilworth, 
NJ) (0.04 mg/kg) was administered intramuscularly 24 hours before the 
blood was collected for neutrophil isolation. Control animals 
received no treatment. 
Neutrophil preparation. Neutrophils were separated as previously 
described (Lukacs, Roth, and Kaeberle, 1985). Briefly, peripheral 
blood was collected from healthy cattle into acid-citrate-dextrose 
solution, centrifuged, and the plasma and buffy coat layer were 
discarded. The packed erythrocytes were lysed by brief exposure to 
hypotonic conditions and the remaining cells, which generally 
consisted of greater than 90% polymorphonuclear leukocytes (PMNS), 
were washed in 0.015 M phosphate buffered saline solution (PBS) (pH 
7.2) and suspended in Medium 199, containing 25 mM HEPES buffer, to a 
concentration of 1.0 X 10® PMN/ml. 
Treatment of PMNs with rboIFN-gamma. Three hundred microliters of 
a 1.0 X 10®/ml suspension of PMN were incubated with 300 ul of rboIFN-
gamma (5.0 X 10~® gm/ml final concentration) (diluted in Medium 199 
with HEPES) for 2.5 hours at 37°C. The PMNs were then used in the 
functional assays without washing. Control PMN preparations were 
incubated with Medium 199 with HEPES. The bovine rboIFN-gamma was 
supplied by Genentech Inc., South San Francisco, CA. (Lot number 
2433/21,33,95) with a specific activity of > 1.0 X 10® U/mg (MDBK-
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VSV). 
Evaluation of neutrophil function. The procedure for evaluation 
of random migration under agarose, ADCC and AINC have previously been 
described (Lukacs, Roth, and Kaeberle, 1985). 
Inhibitor studies. Alpha-amanitin and puromycin or cycloheximide 
(Sigma Chemical Co., St. Louis, Mo.) were used to inhibit RNA and 
protein synthesis respectively during the incubation of PMNs in the 
presence or absence of rboIFN-gamma. PMNs were first preincubated 
with alpha-amanitin (50 ug/ml), puromycin (10 ug/ml) or cycloheximide 
for 30 min at 37°C; medium + rboIFN-gamma containing the same 
concentration of inhibitor(s) was then added to the PMNs (without 
washing) and the incubation continued for 2.5 hours. 
Incorporation of L-[^^S]methionine and 5,6-^H-uridine. Purified 
*7 
PMNs (1.0 X 10 ) were plated in 22 mm tissue culture dishes (12 well 
Costar 3512, Costar, Cambridge, MA) in 100 ul of RPMI 1640 medium 
(Select-amine kit 300-7402, Gibco, Santa Clara, CA) supplemented with 
50 uM methionine in an atmosphere of 5% C02/95% air at 37°C either in 
the presence or absence of RNA or protein synthesis inhibitors. After 
30 minutes the cultures received 300 ul of the same medium containing 
150 uCi of L-C^^]S-methionine or 10 uCi of 5,6-^H-uridine with or 
without rboIFN-gamma and with or without inhibitor. The cells were 
resuspended by gentle pipetting 3.5 hours later, centrifuged to remove 
conditioned medium, washed twice by centrifugation in cold PBS 
containing 10 mM EDTA, and solubilized in 200 ul of lysis buffer (0.5% 
Nonidet 40, 20 mM HEPES, ImM EDTA) plus ImM phenylmethylsulphonyl 
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fluoride and ImM aprotinin (100 U). Nuclei were pelleted by 
centrifugation (2500 x g, 15 min, 4°C, Jouan Cr.411 E4 rotor). The 
fractions (conditioned medium, nuclei, and postnuclear supernatants) 
were subjected to tri-chloroacetic acid (TCA) precipitation and part 
of each sample was prepared for sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-page). 
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Kinetic labeling and PMN fractionation. L-C S]-me.thionine 
labeling conditions were as described above. The cells were 
resuspended by gentle pipetting at either 60, 120, or 180 minutes 
later, centrifuged at 4°C to remove conditioned medium, washed twice 
by centrifugation in cold PBS containing 10 mM EDTA, and mechanically 
disrupted through a 20 gauge needle (20 strokes) in cold 10 mM PIPES 
buffer, pH 7.0 containing 100 mM KCl, 3 mM NaCl, 3.5 mM MgClg, 1 mM 
phenylmethylsulphonyl fluoride and 1 mM aprotinin (100 U). Nuclei 
were pelleted as described above, then granules and plasma membranes 
were pelleted sequentially from the remaining supernatant by 
centrifugation (20,000 x g, 15 minutes and 122,000 x g, 60 minutes, 
4°C, Beckman airfuge-ultracentrifuge A-100/18 rotor). The final 
supernatant (cytosol) and the granule pellet were then subjected to 
SDS-page. 
SDS-page and X-ray film detection of L-C^^S]-methionine-labeled 
proteins. SDS-page (linear gradient of 7.5 to 15% acrylamide) was 
performed according to a modified Laemmli procedure previously 
described in detail (Nilsen-Hamilton and Hamilton, 1979). Sample 
preparation was also described (Nilsen-Hamilton and Hamilton, 1979). 
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Detection of [ S] in polyacrylamide gels by scintillation 
autoradiography (fluorography) using X-ray film was performed 
according to the procedure of Bonner and Laskey (1974). 
TCA precipitation of radiolabeled molecules. An equal volume of 
cold 1.0 M Tris-HCl (pH 10.7) and sample were combined, the mixture 
was incubated for 15 min at 37°C and applied (2.5 ul) to the bottom of 
a (5 X 1 cm) polysilicic acid impregnated glass fiber strip 
(chromatography medium c4943-32/ American Scientific Products, McGraw 
Park, IL). Separation by ascending thin layer chromatography for 10 
min took place in a covered glass chamber containing 0.5 ml of solvent 
(30% v/v methanol, 20% w/v TCA, 10% v/v glacial acetic acid in water). 
Nonincorporated L-[ S]--methionine migrated with the solvent front and 
was discarded by cutting the strip cross-wise (1.5 cm from the 
bottom). The TCA precipitated proteins remained at the application 
site (0.8 cm from the strip bottom), the strip was dried, and counted 
in a toluene-based scintillation fluid (Liquifluor, New England 
Nuclear, Boston, MA) in a liquid scintillation counter (Packard 
Instrument Co., Inc., Downers Grove, 111). 
Arachidonic acid lipoxygenase inhibitors. BW755c was a gift from 
Wellcome Research Laboratory (Kent, United Kingdom) and 
nordihydroguaiaretic acid (NDGA) was purchased from Sigma (Sigma 
Chemical Co., St. Louis, MO). Both compounds were initially dissolved 
in dimethyl sulfoxide (DMSO) immediately before use and diluted in 
0.015 M phosphate buffered saline solution (pH 7.2) (PBS) to a final 
concentration of 1.0 mg/ml. These inhibitors were then added to the 
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PMNs after incubation with rboIFN-gamma (in M199) to give a final 
concentration of 50 ug/ml immediately before the cells were added to 
the functional assays. The DMSO was present at a 0.05% concentration; 
this concentration of DMSO in PBS was found to have no effect on 
neutrophil function. 
Data analysis. A PMN preparation from each animal was aliquoted 
to receive all in vitro control and inhibitor treatments in both the 
presence and absence of rboIFN-gamma. Statistical significance was 
determined by using a paired comparison analysis. The value for a PMN 
preparation in the presence of rboIFN-gamma was compared to the value 
from an aliquot of that same PMN preparation similarly treated (+ 
inhibitor) in the absence of rboIFN-gamma. The individual PMN 
preparations were used as blocking factors in the analysis of variance 
in order to remove the animal to animal variability from statistical 
consideration of the treatment effect. 
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RESULTS 
Neutrophils (PMNs) were isolated from both dexamethasone-treated 
and nontreated cattle (control) and half of each aliquot of cells was 
incubated (2.5 hr) in medium with or without rboIFN-gamma before being 
added to the assays. The PMNs from dexamethasone-treated cattle had 
greatly enhanced random migration under agarose as compared to the 
PMNs from untreated cattle (control) (Figure la). The pretreatment of 
PMNs from either control or dexamethasone-treated cattle with rboIFN-
gamraa inhibited neutrophil random migration under agarose. The 
rboIFN-gamma was able to reduce random migration by PMNs from 
dexamethasone-treated cattle to values similar to those of PMNs from 
control cattle. 
Pretreatment of control PMNs with rboIFN-gamma also resulted in an 
increased percentage of ^^Cr release from antibody-coated chicken 
erythrocytes (CRBCs) in the antibody-dependent cell-mediated 
cytotoxicity (ADCC) assay (Figure lb). Intramuscular injection of 
dexamethasone reduced the neutrophil ADCC, but this activity was 
restored to control values following in vitro rboIFN-gamma treatment. 
Similarly, the ^ ^Cr release from nonantibody-coated CRBCs (AINC) was 
increased after rboIFN-gamma pretreatment of control PMNs (Figure Ic). 
The PMNs from dexamethasone-treated cattle, however, had a complete 
lack of AINC activity (~1.0%) which was not increased by rboIFN-gamma 
pretreatment (Figure Ic). 
The need for RNA and protein synthesis by neutrophils pretreated 
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with rboIFN-gamma for the inhibition of random migration and 
enhancement of AINC was investigated using alpha-amanitin (50 ug/ml)/ 
cycloheximide (5 ug/ml)/ and puromycin (10 ug/ml). At these 
concentrations the inhibitors did not affect PMN viability as 
determined by trypan blue exclusion (>95% viable). Inhibition of RNA 
and protein synthesis by alpha-amanitin and puromycin, respectively, 
blocked the inhibition of random migration by rboIFN-gamma (Figure 
2a). Cycloheximide at a 5 ug/ml concentration partially blocked the 
inhibition of neutrophil random migration by rboIFN-gamma, a 
concentration of 10 ug/ml was required to block this activity 
completely (data not shown). These inhibitors were also able to block 
the enhancement of AINC activity by rboIFN-gamma (Figure 2c). Figure 
2b indicates the ADCC enhancement by rboIFN-gamma was not affected by 
the presence of RNA or protein synthesis inhibitors. 
The amount of L-[ S]-methionine incorporation (3.5 hr) into new 
protein by PMNs was determined by TCA protein precipitation. The 
incorporation of radiolabel was inhibited by 90% in both rboIFN-gamma 
treated and nontreated control PMN fractions that received either 
cycloheximide (5 ug/ml) or puromycin (10 ug/ml) (Table 1). The 
OC 
specific incorporation of L-[ S]-methionine into protein was verified 
by adding radiolabeled methionine, stopping the reaction immediately 
(zero-minute incubation), and determining the TCA precipitable cpms. 
Table 1 also shows that addition of alpha-amanitin reduced the 
incorporation of 5,6-^H-uridine into TGA-precipitable RNA by 
approximately 95%. 
Figure 1. Effects of in vitro incubation with rboIFN-gamma on 
random migration and cytotoxicity of PMNs from dexametha­
sone-treated and nontreated cattle (control). PMNs were 
purified from control and dexamethasone-treated cattle, 
then incubated in Medium 199 for 2.5 hours in the presence 
or absence of 5 X 10 gm/ml rboIFN-gamma before being 
added to the functional assays. Results are the mean 
+ SEM (n=6). ^ P < 0.01; P < 0.05; the level of 
statistical significance for the difference between the in 
vitro rboIFN-gamma treatment value and the value for the 
same neutrophils in the absence of rboIFN-gamma. Separate 
analyses on dexamethasone-treated and control cattle were 
performed 
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Figure 2. Effects of inhibitors of RNA and protein synthesis on the 
inhibition of neutrophil random migration and the enhance­
ment of neutrophil cytotoxicity by rboIFN-gamma. PMNs 
were preincubated with 25 ug/ml alpha-amanitin, 10 ug/ml 
puromycin, or 5 ug/ml cycloheximide for 30 minutes at 37°C, 
and then for 2.5 hours in the presence or absence of 
5 X lO" gm/ml rboIFN-gamma + inhibitor before being added 
to the functional assays. Results are the mean + SEM 
(n=6). ^ P < 0.01; P < 0.05; the level of statistical 
significance for the difference between paired bars 
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Table 1. Effect of inhibitors of ENA and protein synthesis on 
[5/6- H]-uridine or L-C S]-methionine incorporation 
into acid-precipitable RNA or protein 
L - [ m e t h i o n  i n e  [5/5- H]uridine 
(cpm X 10^) (cpm X 10 ) 
Pretreatment of PMNs® PMN + RPMI PMN + IFN PMN + RPMI PMN + IFN 
RPMI 1640 4.80 
zero-labeling time 0.51 
Cycloheximide (5 ug/ml) 0.49 
Puromycin (10 ug/ml) 0.43 
alpha-amanitin (25 ug/ml 1.50 
3.90 2.40 3.10 
0.43 
0.48 
1.50 0.05 0.16 
^MNs (1.0 X 10 PMN) were pretreated by incubation in RPMI 
1540 medium 5 ug/ml cycloheximide/ 10 ug/ml puromycin/ or 25 ug/ml 
of alpha-amanitin for 30 minutes at 37°C/ and then for 3.5 hours in 
the presence or absence of rboIFN-gamma (5 X 10" gm/ml inhibitors) 
containing a final concentration of 50 uCi of L-[ S]methionine or 
7.5 uCi [5/6- Hjuridine before being assayed. The values presented 
are the average of 3 animals. There was no significant difference 
between the values in the presence or absence of rboIFN-gamma. 
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PMNs from dexamethasone-treated and nontreated cattle were 
gC 
incubated in the presence of L-[ S]~methionine for 3.5 hours with and 
without added rboIFN-gamma. No protein bands were detectable on 
fluorograms in either the presence of puromycin or after a zero-minute 
incubation time with L-[ Sj-methionine (Figure 3). Equal numbers of 
PMNs were radiolabeled/ solubilized in NP40 lysis buffer, and cell 
fractions were separated by centrifugation. The supernatants 
remaining after the nuclear material was centrifuged out were 
separated on SDS-polyacrylamide linear gradient (7.5-15.0%) gel 
electrophoresis in the presence of 2.0% 2-mercaptoethanol. 
Approximately equal TCA-precipitable cpms were loaded onto the gel for 
both rboIFN-gamma treated and nontreated PMNs and compared. Only one 
major quantitative protein change was apparent in the postnuclear 
fraction after rboIFN-gamma treatment (typical data for 6 different 
animals analyzed on separate days). The PMNs labeled in the absence 
of rboIFN-gamma had a protein triplet with apparent molecular weights 
59, 50, and 62 kilodaltons. Whereas, only the protein band with an 
apparent molecular weight of 60 kilodaltons was increased in the 
presence of rboIFN-gamma (Figure 3). PMNs from both dexamethasone-
treated and nondexamethasone-treated (control) cattle showed the same 
triplet in the absence of rboIFN-gamma and the 60 kilodalton protein 
induction in the presence of rboIFN-gamma. 
Figure 3. Representative fluorogram (of 6 replicates) of PMN L-[ S]-
methionine-labeled proteins subjected,to SDS-polyacryl-
amide, linear-gradient (7.5-15%) electrophoresis. PMNs 
(1.0 X 10 ) from dexamethasone-treated and nontreated 
cattle were pretreated by incubation in RPMI 1540 medium 
10 ug/ml puromycin or 25 ug/ml of alpha-amanitin for 
30 minutes at 37 C, and then for 3.5 hours in the presence 
or absence of rboIFN-gamma (5 X 10" gm/ml + inhibitors) 
containing a final-concentration of 50 uM cold methionine 
and 50 uCi of L-[ S]-methionine before being prepared for 
SDS-PAGE. The lanes contain NP40-solubilized postnuclear 
fractions from: Lane 1, non-treated cattle (control) PMNs 
in the presence of puromycin; lane 1, control PMNs sub­
jected to a zero-minute labeling incubation time; lane 3, 
control PMNs; lane 4, control PMNs treated with rboIFN-
gamma; lane 5, control PMNs in the presence of alpha-aman-
itin; lane 6, control PMNs treated with rboIFN-gamma and 
alpha-amanitin; lane 7/ PMNs from dexamethasone-treated 
cattle; and lane 8, PMNs from dexamethasone-treated cattle 
treated with rboIFN-gamma in vitro 
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Alpha-amanitin decreased the amount of L-[ S]-methionine 
incorporation into PMN proteins (Table 1). In addition, the protein 
labeling was less intense on the fluorogram in both control and 
rboIFN-gamma treated PMNs (Figure 3). There was no increase in the 60 
kd protein with rboIFN-gamma treatment in the presence of alpha-
amanitin. 
The control cattle PMNs were then incubated in the presence of L-
OÇ 
C S]-methionine with and without added rboIFN-gamma for various 
lengths of time. After incubation for 60, 120, or 180 minutes, the 
PMNs were fractionated so that changes in cytosolic proteins could be 
evaluated. Figure 4 represents typical kinetic data (6 different 
animals analyzed on separate days) the kinetics of the rboIFN-gamma 
induced increase in a cytosolic 60 kd protein. No increase in this 
protein was detected at 60 minutes, by 120 minutes the increase was 
apparent and the increase in expression continued through 180 minutes 
of incubation with rboIFN-gamma. 
Figure 5 represents the kinetics of the rboIFN-gamma induced 
increase in expression of the 60 kd protein in the granule/granule-
associated fraction from the above mentioned cells. The increase in 
the 60 kd protein occurred between 120 and 180 minutes of incubation 
with rboIFN-gamma. Recombinant IFN-gamma also induced the expression 
of a protein in the granule/granule-associated fraction with an 
apparent molecular weight of 93-94 kd. The induction of this protein 
occurred between 60 and 120 minutes of incubation with rboIFN-gamma. 
The 93-94 kd protein was also visible in the cytosolic fraction 
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(Figure 4) after a similar incubation period. Both the 60 and 93-94 
kd proteins were present at a greater percentage of the total protein 
in the granule/granule-associated fraction (Figure 5) than they were 
in the cytosolic fraction (Figure 4). 
The addition of inhibitors of arachidonic acid lipoxygenase 
metabolism (NDGA and BW755C) after rboIFN-gamma pretreatment or to the 
control PMNs had no statistically significant effect on random 
migration (Figure 6a) or ADCC activities (Figure 6b). However, these 
inhibitors decreased the background AINC activity in the absence of 
rboIFN-gamma and markedly decreased the AINC activity in the presence 
of rboIFN-gamma (Figure 6c). The NDGA was more effective than the 
BW755c at the same concentrations. 
Figure 4. Representative fluorogram (of 6 replicates) of radiolabeled 
neutrophil cytosolic proteins loaded onto an SDS-polyacryl-
amide, linear-gradient gel (7.5-15%). PMNs (1.0 X 10 ) 
from nontreated cattle were incubated in RPMI 1640_medium 
containing 50 uM cold methionine and 50 uCi of L-[ S]-
methionine for 60/ 120, or 180 minutes at 37°C in the 
presence or absence of rboIFN-gamma (5 X 10" gm/ml). The 
cells were fractionated and approximately equal acid-pre-
cipitable cpms of cytosolic protein were loaded onto the 
gel. The lanes contain the labeled cytosolic fractions from 
PMNs labeled for 60 minutes in the absence or presence of 
rboIFN-gamma (lanes 1 and 2), PMNs labeled for 120 minutes 
in absence or presence of rboIFN-gamma (lanes 3 and 4), and 
PMNs labeled for 180 minutes in the absence or presence of 
rboIFN-gamma 
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Figure 5. Representative fluorogram (of 6 replicates) of radiolabeled 
neutrophil granule/granule-associated proteins loaded onto 
an SDS-polyacrylamide, linear-gradient gel (7.5-15%). PMNs 
from nontreated (control) cattle were incubated in RPMI 
1640 medium containing 50 uM cold methionine and 50 uCi of 
L-[ S]-methionine for 60/ 120, or 180 minutes at 37 °C in 
the presence or absence of rboIFN-gamma (5 X 10" gm/ml). 
The cells were fractionated and approximately equal TCA-
precipitable cpms were loaded onto the gel. The lanes 
contain the labeled granule/granule-associated fractions 
from PMNs labeled for 60 minutes in the absence or presence 
of rboIFN-gamma (lanes 1 and 2), PMNs labeled for 120 
minutes in absence or presence of rboIFN-gamma (lanes 3 
and 4)/ and PMNs labeled for 180 minutes in the absence or 
presence of rboIFN-gamma 
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Figure 6. Effects of inhibitors of arachidonic acid metabolism on 
the inhibition of neutrophil random migration and enhance­
ment of cytotoxicity. PMNs were incubated 2.5 hours in the 
presence or absence of 5 X 10" gm/ml of rboIFN-gamma/ 
and just before being assayed the cells were incubated with 
either 50 ug/ml BW755c/ 25 ug/ml NDGA, or M199 medium with­
out inhibitors. Results are the mean ^  SEN (n=5). 
P < 0.01; P < 0.05; the level of statistical 
significance for the difference between paired bars 
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DISCUSSION 
Preincubation with rboIFN-gamma in vitro (2.5 hr) reversed the in 
vivo dexamethasone effects on random migration and ADCC (Figures la, 
lb) to approximately control values. Previous reports indicate that 
corticosteroids inhibit lymphokine production (e.g., gamma interferon) 
(Cesario et al., 1986). These results suggest that rboIFN-gamma might 
be useful as an immune enhancing agent in glucocorticoid-induced 
immunosuppression. However, there was no enhancement of AINC after 
rboIFN-gamma pretreatment of PMNs from dexamethasone-treated cattle 
(Figure Ic). This result was in direct contrast to the enhancement of 
the AINC activity of control PMNs pretreated with rboIFN-gamma (Figure 
Ic). In fact, the dexamethasone treatment reduced the AINC to 
baseline level and rboIFN-gamma was unable to raise these values. The 
difference in the rboIFN-gamma activation of PMNs from these two 
sources provided a means of determining the molecular events required 
for the enhancement of AINC; events not required for the enhancement 
of the ADCC activity. 
We have previously reported the need for RNA and protein synthesis 
for the inhibition of neutrophil random migration by rboIFN-gamma 
(Steinbeck, Roth, and Kaeberle, 1986). In addition, our laboratory 
has reported that inhibition of RNA and protein synthesis with 
actinomycin D and puromycin decreased a lymphokine induced enhancement 
of AINC but had no effect on ADCC (Lukacs, Roth, and Kaeberle, 1985). 
The use of RNA and protein synthesis inhibitors demonstrated the need 
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for these molecular events in the rboIFN-gamma enhancement of AINC 
(Figure 2c) but not ADCC (Figure 2b) activity. Protein synthesis 
could be necessary for induction and expression of adherence molecules 
(involved in target cell binding) or for a protein(s) that plays a 
role in the enhancement of the AINC activity (cytotoxic factor). 
The rboIFN-gamma treated PMNs had an increase in a 60 kd cytosolic 
or granule/granule-associated protein. The importance or function of 
this protein is unknown, but represents a consistent change after 
rboIFN-gamma treatment. In the presence of alpha-amanitin there was 
no increase in the 60 kd protein made by rboIFN-gamma treated PMNs 
(Figure 3). This suggests that RNA synthesis must take place prior to 
a detectable increase in this protein. The kinetics indicate that the 
expression of this intracellular protein was not increased until after 
60 minutes of incubation with rboIFN-gamma and before 120 minutes. 
This time period was consistent with the time required for AINC 
enhancement (Lukacs, Roth/ and Kaeberle, 1985). However, the presence 
of this protein alone was not enough to enhance the AINC activity of 
PMNs from dexamethasone-treated cattle. 
Inhibitors of the formation of arachidonic acid lipoxygenase 
products (NDGA and BW755c) also inhibited the enhancement of AINC by 
rboIFN-gamma (Figure 5c). These inhibitors were added after the 
rboIFN-gamma pretreatment to allow the essential protein synthesis to 
take place. Dexamethasone is known to induce the synthesis of 
lipomodulin in PMNs from several different animal species (Hirata et 
al./ 1980; Blackwell et al./ 1983) which then acts to inhibit 
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phospholipase and ultimately the release of arachidonic acid from 
membrane phospholipids. The released arachidonic acid is normally 
converted in nontreated bovine neutrophils via the lipoxygenase 
pathway into two major metabolic products, leukotriene and 5-HETE 
(Webb and Roth, 1987). Both leukotriene B^ and 5-HETE can act as 
chemotaxins for bovine neutrophils (Palmer et al., 1980). Leukotriene 
2+ 
can also induce increased Ca mobilization and degranulation 
(Naccache et al., 1984; Palmer and Salmon, 1983). In addition, 5-HETE 
can be reincorporated into membrane phospholipids and cause membrane 
fluidity changes (Bonser et al., 1981; Stenson and Parker, 1979). 
Leukotriene B^ and 5-HETE are essential for an optimal iodination and 
oxidative response by bovine neutrophils to opsonized-zymosan 
stimulation (Webb and Roth, 1987). 
It has been reported by several research groups, that oxidative 
2+ 
metabolism, extracellular degranulation, and Ca play a major role in 
antibody-dependent and -independent neutrophil-mediated cytotoxicity. 
Oxidative metabolism was necessary for ADCC activity against tumor 
cells (Clark and Klebanoff, 1977; Hafeman and Lucas, 1979) and human 
RBCS (Borregaard and Kragballe, 1982) but oxidative metabolism was not 
required for killing of antibody-coated, virus-infected cells 
(Siebens, Tevethia, and Babior, 1979), CRBC (Cordier and Revillard, 
1980), and lymphocytes (Katz et al., 1980). Cationic proteins from 
bovine neutrophil granules have been implicated in the ADCC activity 
against IBR-infected target cells (Thorne et al., 1984). Antibody-
independent killing by oxidative mechanisms has been reported in 
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lectin-induced neutrophil lysis of CROC (Simchowitz and Spilberg, 
1979) and PMA-induced neutrophil lysis of tumor cells (Clark and Szot, 
1981) and human erythrocytes (Weiss, 1980). In addition, a membrane-
bound neutral proteinase (300 kd) released from PMA-activated human 
neutrophils was found to work in conjunction with oxidative 
metabolites to lyse ox erythrocytes (Pontremoli et al., 1986). 
Dallegri et al. (1984) reasoned that the target cell lysis depended on 
both intact oxidative and nonoxidative mechanisms, but could be 
influenced by the ability of the target to overcome the effects of the 
oxidative products. The arachidonic acid lipoxygenase products are 
essential for optimal production of both oxidative and nonoxidative 
(degranulation) factors which are effectors of the cytolytic activity 
(primarily AINC). The arachidonic acid products do not seem to play a 
role in either random migration enhancement by dexamethasone or 
inhibition by rboIPN-gamma (Figure 5a). 
In addition to the above mentioned cytolytic factors, surface 
adherence proteins are also required for normal ADCC activity (Kohl et 
al., 1984; Lopez et al., 1985). The adherence of PMNs is mediated by 
a family of surface glycoproteins, LFA-1, iC3b/Mol/0KM-l/Mac-l, and 
P150,95. These proteins have a common 95 kd beta subunit and variable 
alpha subunits. GFA-2 is another glycoprotein belonging to this 
family that is expressed only on mature PMNs, and consists of a single 
95 kd subunit (Lopez et al., 1985). Binding of a monoclonal antibody 
directed against GFA-2 results in degranulation of cytochalasin B-
pretreated PMNs. Gamma interferon is known to augment human PMN 
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adherence (Seow and Thong, 1986), presumably by effecting the 
expression of these surface glycoproteins. It is possible that the 
93-94 kd protein induced by rboIFN-gamraa (Figures 4, 5) is an 
adherence glycoprotein involved in both migration inhibition 
(inversely related functions) and AINC PMN-target cell binding. 
In summary, the metabolic events, associated with neutrophil 
activation by rboIFN-gamma, are different for the three functions 
measured by these assays. Migration inhibition required both RNA and 
protein synthesis, but did not require arachidonic acid metabolism. 
Enhancement of ADCC did not require mRNA transcription, protein 
synthesis, or arachidonic acid metabolism. On the other hand, AINC 
enhancement required mRNA transcription, protein synthesis, and 
arachidonic acid metabolism. Clearly, neutrophils are metabolically 
active cells which can be stimulated to even greater functional 
activity by rboIFN-gamma. These data help to explain the mechanisms 
by which rboIFN-gamma enhances nonspecific resistance to infectious 
disease. 
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ABSTRACT 
Recombinant bovine gamma interferon (rboIFN-gamma) at 10 or 50 
units/5.0 X 10^ neutrophils enhanced bovine neutrophil cytotoxicity 
against ^^Cr-labeled chicken erythrocytes (CRBCs) in the presence and 
absence of anti-CRBC antiserum. Both concentrations of rboIFN-gamma also 
inhibited bovine neutrophil random migration under agarose. Human gamma 
interferon (huIFN-gamma) at 10 units/5.0 x 10^ cells, inhibited human 
neutrophil random migration and enhanced neutrophil-mediated lysis of 
CRBCs, but only in the presence of anti-CRBC antiserum. Human IFN-gamma, 
at 50, 500, or 1000 units, did not affect bovine neutrophil cytotoxic 
activity or random migration. Interestingly, the enhancement of bovine 
antibody-independent neutrophil cytotoxicity (AINC) by rboIFN-gamma, but 
not the enhancement of antibody-dependent cell-mediated cytotoxicity 
(ADCC), was influenced by the medium chosen for pretreatment and assay. 
Bovine neutrophils were preincubated for 2 hours and then assayed in 
either M199, MEM, or RPMI 1640 with or without 10 units of rboIFN-gamma. 
The mean increase in AINC due to rboIFN-gamma treatment was significantly 
greater in M199 than in MEM, in RPMI 1640 there was little or no increase 
in this activity. Addition of three components unique to M199 components 
(ATP, ascorbic acid, and tween 80), which are known to affect other 
neutrophil functions, to both MEM or RPMI 1640 did not significantly 
affect the enhancement of AINC. In conclusion: 1) human neutrophils are 
not induced by human gamma interferon to have AINC activity under the 
same conditions in which rboIFN-gamma enhances bovine neutrophil AINC, 2) 
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huIFN-gamma has no effect on bovine neutrophil random migration or 
cytotoxicity/ and 3) medium components are important for the maximal 
enhancement of bovine neutrophil AINC activity by rboIFN-gamma. 
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INTRODUCTION 
We have previously reported the enhancement of bovine neutrophil 
cytotoxicity and the impairment of random migration after 2 hours of 
rboIPN-gamma pretreatment (Steinbeck/ Roth, and Kaeberle, 1986). The 
ability to activate bovine neutrophils to lyse chicken erythrocyte (CRBC) 
targets in the absence of anti-CRBC antiserum (AINC) has been of 
particular interest (Lukacs, Roth, and Kaeberle, 1985; Steinbeck, Roth, 
and Kaeberle, 1986). Separate molecular events are involved in the 
activation of neutrophils for lysis of cell targets in the presence and 
absence of target specific antiserum (Steinbeck and Roth, 1987). 
Peripheral blood (resting) neutrophils have the ability to lyse antibody-
coated CRBCs, although to a lesser extent than activated neutrophils. 
However, without being activated, neutrophils are generally not able to 
lyse chicken erythrocyte (CRBC) targets to a significant extent in the 
absence of anti-CRBC antiserum. Richter et al. (1981) have reported 
naturally occurring cytotoxic activity of human neutrophils against 
rabbit, sheep, and ox erythrocyte targets in gamma-globulin depleted 
serum. This cytotoxic activity of nonactivated human neutrophils was 
directed against erythrocyte targets from several species, and it was 
suggested that factors other than immunoglobulins were present in the 
serum that opsonized these targets. The human neutrophils in the study 
by Richter et al. (1981) did not lyse chicken erythrocyte targets in the 
presence of gamma-globulin depleted serum. The ability of activated 
human neutrophils to lyse chicken erythocytes was not investigated. 
115 
Shalaby et al. (1985) have looked at the ability of gamma interferon-
activated human neutrophils to lyse antibody-coated CRBC targets in RPMI 
1640/ and similar to our present findings/ have not reported lysis in 
the absence of antibody in this medium. Richter et al. (1981) assayed 
for/ cytolytic activity of nonactivated human neutrophils in M199/ which 
is the medium used in the cytotoxic assays performed on bovine 
neutrophils. We had never assayed for the bovine cytotoxic activity in 
RPMI 1640 medium or MEM/ which are media generally used in human 
neutrophil cytotoxic assays. Therefore/ the difference in the ability 
of gamma interferon-activated neutrophils from the two species to lyse 
the same target cell under various assay conditions was investigated. 
This was of particular interest/ because M199 has several components 
that are not present in RPMI 1640 or MEM. In addition/ RPMI 1640 has 
higher Ca"*"^/ Mg^/ and glucose concentrations than the other two media. 
Some of the components present in M199 were added to MEM and RPMI 1640 
to determine possible effects on bovine neutrophil cytotoxicity. 
Assaying for random migration under agarose was used as a measure of 
neutrophil activation by gamma interferon (neutrophil migration 
inhibition factor) and neutrophil viability (Classer/ Fiederlein/ and 
Huestis/ 1985). Finally, the ability of human gamma interferon to 
activate bovine neutrophils was evaluated under optimal conditions 
(M199). 
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MATERIALS AND METHODS 
Donors. Bovine neutrophils were obtained from twenty healthy, one 
to two-year-old Holstein steers. Human neutrophils were obtained from 
healthy human volunteers. 
Neutrophil preparation. Bovine neutrophils were separated as 
previously described (Lukacs, Roth, and Kaeberle, 1985). Briefly, 
peripheral blood was collected from healthy cattle into acid-citrate-
dextrose solution, centrifuged, and the plasma and buffy coat layer were 
discarded. The packed erythrocytes were lysed by brief exposure to 
hypotonic conditions and the remaining cells, which generally consisted 
of greater than 95% polymorphonuclear leukocytes (PMNS), were washed in 
0.015 M phosphate buffered saline solution (PBS) (pH 7.2) and 
resuspended in Medium 199, MEM, or RPMI 1640 to a concentration of 1.0 X 
10® PMN/ml. Human peripheral blood was collected into acid-citrate-
dextrose solution, centifuged at lOOOg x 20 minutes, and the plasma and 
upper layer of buffy coat were discarded. The packed erythrocytes were 
lysed (2x) in a 2-fold volume of ice-cold NH^Cl solution (155 mM NH^Cl, 
10 mM KHCOg, and 0.1 mM EDTA, pH 7.4 at 0°C) as previously described 
(Roos and de Boer, 1986). The remaining cells, which consisted of 
greater than 90% neutrophils, were washed in 0.015 M phosphate buffered 
saline solution (pH 7.2) containing 1.Ovalbumin, and resuspended in 
Medium 199, MEM, or RPMI 1640 (Grand Island Biologies Co., Grand Island, 
NY) containing 0.5% albumin to a concentration of 1.0 x 10® PMN/ml. 
Treatment of neutrophils with gamma interferon. Three hundred 
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microliters of a 1.0 x 10 /ml suspension of PMNs were incubated with 300 
ul of human gamma interferon. To each medium the gamma interferons were 
added to the final concentration of 10 or 50 units of bovine 
7 interferon/5.0 x 10 PMNs and 10, 50, 500, or 1000 units of human 
7 interferon/5.0 x 10 PMNs. The PMNs were incubated in the various 
interferon containing media for 2 hours at 37°C in a humidified 
atmosphere of 5% CO^. Noninterferon-treated PMNS were incubated under 
the same environmental and media conditions as the interferon-treated 
neutrophils. The PMNs were then used in the functional assays without 
washing. The rboIFN-gamma was supplied by Ciba-Geigy, Basel, 
Switzerland (Lot number 3229/38) with a specific activity of 1.2 x 
10® U/mg (MDBK-VSV). Human interferon was obtained from Interferon 
Sciences, Inc., New Brunswick, New Jersey with a specific activity of 
0.2 X 10® U/mg (HEp-2-VSV). Other media components added to both MEM 
and RPMI 1640 included ATP (1.0 mg/1), ascorbic acid (0.05 mg/1), and 
tween 80 (20 mg/1) (Sigma Chemical Co., St. Louis, MO). 
Neutrophil random migration. Evaluation of random migration under 
agarose was performed as previously described (Roth and Kaeberle, 1981). 
Agar consisted of bicarbonate-buffered Medium 199 with Earle's salts 
containing 0.8% agarose, 10% fetal bovine serum, and 1% penicillin 
(Grand Island Biological Co., Grand Island, NY) in 60- x 15-mm tissue 
culture grade Petri plates (No. 1007 Falcon, Oxnard, CA). Cells were 
placed into wells cut into the agar, and the Petri plates were placed 
into an incubator with a humidified 5% CO^ atmosphere. Eighteen hours 
later the cells were fixed with 8% glutaraldehyde for 30 minutes, the 
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agar removed/ and the cells adherent to the plastic were stained with 
modified Wright's stain. The area of migration was determined and 
expressed in square millimeters. 
Cytotoxicity assay. The procedures for evaluation of antibody-
dependent cell-mediated cytotoxicity (ADCC) and antibody-independent 
neutrophil-mediated cytotoxicity (AINC) have previously been described 
(Lukacs/ Roth, and Kaeberle, 1985). Briefly, the ADCC and AINC assays 
were performed in standard microtiter plates utilizing ^^Cr-labeled 
chicken red blood cells (CRBC) as target cells. The standard reaction 
mixtures contained 1.25 x 10^ CRBC and 1.25 x 10® granulocytes 
(effector-to-target ratio of 10:1) in 150 ul of medium with or without 
2.5% bovine anti-CRBC serum. Human PMNs were capable of binding to and 
lysing bovine antibody coated CRBCs, so rabbit anti-CRBC antiserum was 
not used. The AINC assay is performed in the absence of added serum or 
albumin. The medium used in the pretreatment step was also the medium 
used in the cytotoxicity assays. Triton-X controls, antibody controls, 
and granulocytes controls were included. After 2 hours of incubation a 
37°C in a humidified 5% COg atmosphere, the supernatant was collected 
for gamma counting by using the Skatron Supernatant Collection System 
(Skatron, Inc., Sterling, VA). The results were expressed as the 
percentage of specific ^^Cr release. 
Data analysis. A PMN preparation from each donor was aliquoted to 
receive all in vitro treatments in both the presence and absence of 
gamma-interferon. Statistical significance was determined by using a 
paired comparison analysis. The value for a PMN preparation in the 
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presence of IFN-gamma was compared to the value from an aliquot of that 
same PMN preparation in the absence of IFN-gamma. The individual PMN 
preparations were used as blocking factors in the analysis of variance 
in order to remove the animal to animal variability from statistical 
consideration of the treatment effect. 
120 
RESULTS 
Preincubation of bovine neutrophils for 2 hours with recombinant 
bovine gamma interferon (rboIFN-gamma), but not human gamma interferon, 
(huIFN-gamma) enhanced neutrophil cytotoxicity in vitro. The enhanced 
cytotoxic activity against ^^Cr-labeled chicken erythrocytes (CRBCs) 
took place in both the presence and absence of anti-CRBC antiserum. 
This increase is represented in Figure 1 as the difference in the 
percent of ^ ^Cr released from CRBCs by neutrophils after IFN-gamma 
pretreatment (activated) as compared to nontreated neutrophils from the 
same animal. The enhancement of antibody-dependent (ADCC) and 
-independent (AINC) neutrophil-mediated cytotoxicity was induced by 10 
n 
or 50 units (per 5.0 x 10 neutrophils) of rboIFN-gamma (Figure 1). 
Either dose of rboIFN-gamma enhanced AINC or ADCC to approximately the 
same value. Under similar conditions, 50, 500, or 1000 units of huIFN-
gamma failed to affect the cytotoxic activity of bovine neutrophils 
(Figure 1). 
Random migration of bovine neutrophils under agarose was inhibited 
after a 2 hour pretreatment with 10 or 50 units of rboIFN-gamma (Figure 
2). Although there was a tendency for random migration to be decreased 
by the higher concentrations of huIFN-gamma the differences were not 
statistically significant (P > 0.05) (Figure 2). 
Figure 1. Influence of in vitro incubation with bovine and human 
gamma interferon on bovine neutrophil cytotoxicity in 
Medium 199. PMNs were purified and then incubated in 
Medium 199 for 2 hrs in the presence or absence of 10 or 
50 units/5.0 x 10 PMNs of rboIFN-gamma or 50, 500, or 
1000 or units/5.0 x 10 PMNs before being added to the 
AINC and ADCC assays. Results are the mean differences 
(j^ SEM) in the percent of Cr release between inter­
feron treated and nontreated. PMNs isolated from the same 
animal (n=7). ^ P < 0.01; P < 0.05; the level of 
statistical significance for the difference between the 
interferon-treated and nontreated values 
122 
CYTOTOXICITY 
a a 
-
a 
i 
b 
M AINC 
0 ADCC 
a P<0.01 
b P<0.05 
wmXMM laliisiLJC™ 1 1 Jsssi 
10 50 50 500 1000 
units units units units units 
bovine 
rIFN-gamma 
human 
IFN-gamma 
Figure 2. Influence of in vitro incubation with bovine and human 
gamma interferon on bovine neutrophil random migration in 
Medium 199. PMNs were purified and then incubated in 
Medium 199 for 2 hrs in the presence or absence of 10 or 
50 units/5.0 x 10 EMNs of rboIFN-gamma or 50, 500, or 
1000 units/5.0 x 10 PMNs before being added to the 
random migration assay. Results for the interferon-
treated and nontreated neutrophils are the expressed as 
mean percent of nontreated-neutrophil random migration 
(+ SEM) by PMNs isolated from the same animal (n=7). 
P < 0.01; P < 0.05; the level of statistical 
significance for the difference between the interferon 
treated and nontreated values 
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Interestingly; the medium chosen for pretreatment and assay affected 
the amount of enhancement of bovine neutrophil AINC activity by rboIFN-
gamma. Three commercially prepared media, often used in neutrophil 
cytotoxic assays, were compared for their abilities to support the 
induced AINC activity. Neutrophils from the same animals were incubated 
and assayed in all three media on the same day, under the same 
environmental conditions. Nonactivated neutrophil AINC values were 
minimal and nearly the same in all three media. There was significant 
enhancement of neutrophil AINC activity in M199 or MEM after a 2 hour 
pretreatment containing 10 units of rboIFN-gamma (Figure 3). The 
enhancement of AINC tended to be higher when performed in M199 than in 
MEM (Figure 3). Little or no increase in the AINC activity of 
neutrophils occurred after pretreatment and assay in RPMI 1640, several 
values were less than those of the nontreated neutrophil. A comparison 
of the AINC values for the rboIFN-gamma treated neutrophils in the three 
media indicated that the percent of ^^Cr release in RPMI 1640 was 
significantly less (P < 0.05) than in the other two media. 
The values ADCC by noninterferon-treated bovine neutrophils was the 
same in M199 and MEM. The ADCC values for nontreated PMNs incubated in 
RPMI 1640 were significantly higher than those in M199 (P < 0.01) and 
tended to be higher than those in MEM. The ADCC values for the gamma 
interferon-activated neutrophils were approximately the same, regardless 
of the assay medium. The differences in the percent ^^Cr release 
between rboIFN-gamma-treated and nontreated neutrophils in the ADCC 
assay performed in RPMI 1640 (Figure 3) were significantly (P < 0.05) 
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lower than in either M199 or MEM. This was due to higher values for 
nontreated neutrophil ADCC activity in RPMI 1640. The inhibition of 
random migration under agarose (Figure 4) was the same in all three 
media. 
Figure 3. Influence of in vitro incubation with bovine gamma 
interferon on bovine neutrophil cytotoxicity in Medium 199, 
MEM/ and RPMI 1640. PMNs were purified and then incubated 
in medium for 2 hrs in the presence or absence of 10 
units/5.0 X 10 PMNs of rboIPN-gamma before being added 
to the AINC and ADCC assays. Results are the mean differ­
ences (+ SEM) in the percent of Cr release between 
interferon-treated and nontreated. PMNs isolated from the 
same animal (n=5). ® P < 0.01; P < 0.05; the 
level of statistical significance for the difference 
between the gamma interferon treated and nontreated values 
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Figure 4. Influence of in vitro incubation with bovine gamma 
interferon on bovine neutrophil random migration in 
Medium 199, MEM, and RPMI 1640. PMNs were purified 
and then incubated in medium for 2 hrs in the presence 
or absence of 10/5.0 x 10 PMNs of rboIFN-gamma before 
being added to the random migration assay. Results for the 
interferon-treated neutrophils are expressed as the mean 
percent of nontreated-neutrophil random migration (j- SEM) 
by PMNs isolated from the same animal (n=7). 
^ P < 0.01; P < 0.05; the level of statistical 
significance for the difference between the interferon 
treated and nontreated values 
130 
RANDOM MIGRATION 
a P < 0.01 
b P < 0.05 
Ml 99 MEM RPM11640 
10 units bovine rIFN-gamma 
131 è 
Neither RPMI 1640 nor MEM offered optimal conditions for the rboIFN-
gamma-treated bovine neutrophil to express AINC activity. Three 
components unique to M199 composition were added to both RPMI 1640 and 
MEM to evaluate possible effects, if any, on the cytotoxic activities. 
Figure 5 contains the results of the addition to MEM of adenosine 
triphosphate (1.0 mg/1) and ascorbic acid (0.05 mg/1), either alone or in 
combination. Neither additive had any significant (P > 0.05) enhancing 
effect on neutrophil AINC or ADCC activities in the presence or absence 
of rboIFN-gamma. In fact, activated neutrophils had less ADCC activity 
in MEM supplemented with ATP, but this difference was not statistically 
significant (P > 0.05). Addition of tween 80 (20 mg/1) to MEM lowered 
the AINC (P < 0.05) and ADCC (P < 0.01) values for nontreated 
neutrophils. The enhancement of neutrophil AINC after rboIFN-gamma 
activation in both MEM and MEM containing tween 80, was approximately the 
same (Figure 5). 
The addition of either adenosine triphosphate or ascorbic acid to 
RPMI 1640 had little or no effect on AINC or ADCC activities in the 
presence or absence of rboIFN-gamma (Figure 6). Adding the combination 
of ascorbic acid and ATP to RPMI 1640 increased the rboIFN-gamma-treated 
neutrophil AINC and ADCC activities above those of the nontreated 
neutrophils (Figure 6). The rboIFN-gamma-treated neutrophil values in 
this medium tended to be greater than those in RPMI 1640 medium alone. 
Tween 80 addition to RPMI 1640 lowered (P < 0.05) the values for the 
AINC activity of neutrophils treated with rboIFN-gamma. This additive 
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also had a tendency to lower the ADCC values for the nontreated 
neutrophils/ a response very similar to the addition of this molecule to 
MEM. However/ the difference in percent of ^^Cr release in the ADCC 
assay between treated and nontreated neutrophils was similar in RPMI 
1640 with or without added tween 80 (Figure 6). 
Figure 5. Influence of in vitro incubation with bovine gamma 
interferon on bovine neutrophil cytotoxicity in MEM and 
RPMI 1640 supplemented with ascorbic acid (0.05 mg/1), ATP, 
(1.0 mg/L)/ or tween 80 (20 mg/1). PMNs from each animal 
were purified, aliquoted into each of the media, and 
incubated_for 2 hrs in the presence or absence of 10 units 
/5.0 X 10 PMNs of rboIFN-gamma before being added to the 
AINC and ADCC assays containing the same medium in which 
they were preincubated. Results are the mean differences 
(jf SEM) in the percent of Cr release between inter-
feron-treated and nontreated PMNs isolated from the same 
animal (n=12). ^ P < 0.01; P < 0.05; the level of 
statistical significance for the difference between the 
gamma interferon treated and nontreated values 
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Figure 6. Influence of in vitro incubation with bovine gamma 
interferon on bovine neutrophil random migration in MEM and 
RPMI 1640 supplemented with ascorbic acid (0.05 mg/1), ATP, 
(1.0 mg/L)/ or tween 80 (20 mg/1). PMNs from each animal 
were purified, aliquoted into each of the media, and 
incubated_for 2 hrs in the presence or absence of 10 units 
/5.0 X 10 PMNs of rboIFN-gamma before being added to the 
random migration assay. Results for the interferon-
treated neutrophils are the expressed as mean percent of 
nontreated-neutrophil random migration (+ SEM) by the 
gMNs isolated from the same bovine (n=12T. ® P < 0.01; 
P < 0.05;the level of statistical significance for 
the difference between the interferon treated and 
nontreated values 
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Pretreatment of human neutrophils with 10 units/5.0 x 10^ cells of 
human gamma interferon (huIFN-gamma) for 2 hours resulted in an increase 
in the ADCC activity in both M199 and RPMI 1640 (Figure 7). The percent 
of ^ ^Cr released from antibody-coated CRBCs was not significantly 
increased in MEM. No background AINC activity/ nor enhancement after 
activation, was observed with human neutrophils against ^^Cr-labeled 
CRBC targets under any of the assay conditions (Figure 7). Human 
neutrophil random migration was inhibited to approximately the same 
extent in all three media by 10 units of huIFN-gamma (Figure 8). 
Figure 7. Influence of in vitro incubation with human gamma 
interferon on human neutrophil cytotoxicity in Medium 199, 
MEM, and RPMI 1640. PMNs were purified and then incubated 
in medium for 2 hrs in the presence or absence of 10 
units/5.0 X 10 PMNs of huIFN-gamma before being added 
to the AINC and ADCC assays. Results are the mean differ­
ences (+_ SEM) in the percent of Cr release between 
interferon-treated and nontreated PMNs isolated from the 
same donor (n=6). ® P < 0.01; P < 0.05; the level 
of statistical significance for the difference between the 
gamma interferon treated and nontreated values 
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Figure 8. Influence of in vitro incubation with human gamma 
interferon on human neutrophil random migration in 
Medium 199, MEM, and RPMI 1640. PMNs were purified 
and then incubated in medium for 2 hrs in the presence 
or absence of 10/5.0 x 10 PMNs of huIFN-gamma before 
being added to the random migration assay. Results for the 
interferon-treated neutrophils are expressed as mean 
percent of nontreated-neutrophil random migration (+ SEM) 
by PMNs isolât^ from the same donor (n=6). 
P < 0.01; P < 0.05; the level of statistical 
significance for the difference between the interferon 
treated and nontreated values 
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DISCUSSION 
We have previously reported that recombinant bovine gamma interferon 
activates bovine neutrophils to have enhanced antibody-dependent (ADCC) 
and -independent (AINC) cytotoxicity and impaired migration under agarose 
in M199 (Steinbeck, Roth, and Kaeberle, 1986). Increased ADCC activity 
has also been reported for human neutrophils after human gamma interferon 
treatment in RPMI 1640 (Basham, Smith, and Merigan, 1984; Shalaby et al., 
1985; Perussia et al., 1987). Perussia et al. (1987) have reported the 
lack of induction of human neutrophil AINC against p815y cells by rhuIFN-
gamma. The AINC activity against CRBC targets has also been reportedly 
absent for human neutrophils treated with rhuIFN-gamma. This apparent 
difference in neutrophil function between human and bovine neutrophils 
led us to further investigate the AINC activity of neutrophils from each 
species. We found that human neutrophils activated by huIFN-gamma had 
enhanced ability to lyse CRBC in the presence of bovine anti-CRBC 
antiserum in RPMI 1640 (Figure 7), but did not have enhanced AINC 
activity. This agrees with a previous report by Shalaby et al. (1985). 
The possibility that human IFN-gamma could activate bovine neutrophils 
was also investigated. Human IFN-gamma treatment of bovine neutrophils 
in M199 did not influence AINC, ADCC, or random migration (Figures 1, 2). 
Since the media used on human neutrophils in previous reports has 
been RPMI 1640 and the media used with bovine neutrophils has been M199, 
it was decided to investigate the influence of various media on 
neutrophil activation. The inclusion of rboIFN-gamma in either MEM or 
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M199 resulted in the enhancement of bovine neutrophil AINC activity, 
(Figure 3) although the increase was not as dramatic in the MEM medium. 
The AINC activity of activated bovine neutrophils was not measurable in 
RPMI 1640 (Figure 3). Results for the bovine neutrophil ADCC were the 
same in both M199 and MEM in presence of rboIFN-gamma, variable results 
were obtained in RPMI 1640 (Figures 3, 6). Random migration of bovine 
neutrophils was inhibited to the same degree by rboIFN-gamma in all 
three media (Figure 4). 
The difference in the abilities of the three media to support bovine 
neutrophil AINC induced by rboIFN-gamma was investigated further. MEM 
contains similar (but not identical) concentrations of inorganic salts, 
amino acids, and vitamins as M199, but lacks some of the other 
supplements. MEM served as a base medium to which M199 components could 
be added and their effects evaluated. RPMI 1640, like MEM, is a minimal 
essential medium used routinely on human neutrophils. It contains twice 
the concentration of Ca*^, Mg^, and glucose found in MEM or M199. The 
ability of M199 and MEM to support AINC activity was not due to any 
common medium supplement in these two media that was absent from RPMI 
1640. Three components present in M199 (ascorbic acid, ATP, tween 80) 
were selected to be added to MEM and RPMI 1640 because they have been 
reported to affect other neutrophil functions. Ascorbic acid at a 
relatively high concentration (5 x 10"^ M) has been reported to enhance 
guinea pig peritoneal neutrophil chemotaxis (Dallegri, Lanzi, and 
Patrone, 1980). With lower concentrations (1 x 10"^ M) of ascorbic 
acid, there was an increase in neutrophil chemokinesis and inhibition of 
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chemotaxis. The effect on neutrophil cytotoxic activity was not 
evaluated. M199 also contains several nucleic acid molecules, some of 
which are known to have inhibitory effects on neutrophil function. 
Guanine and adenine, at concentrations similar to those found in M199, 
are capable of producing a slight inhibition of bovine neutrophil MPO-
H202-halide activity (Chiang, Kaeberle, and Roth, 1986; Canning et al., 
1985). ATP has been reported to inhibit lysosomal enzyme secretion 
(beta-galactosidase) by mouse macrophages (Riches et al., 1985), but not 
bovine neutrophil iodination at concentrations found in M199. Tween 80 
(20 mg/1), a fatty acid derivative found in M199, was also added to RPMI 
1640 and MEM. Even though tween 80 is present at a low concentration, it 
might effect the membrane properties of bovine neutrophils or CRBC 
targets. 
Neither the addition of ascorbic acid (0.05 mg/1) nor ATP (1 mg/1) at 
the concentrations found in M199 had any major effect on the bovine 
neutrophil antibody-independent (AINC) cytotoxicity after pretreatment 
with 10 units of rboIFN-gamma in the same medium. This was true whether 
the components were added alone or in combination to MEM or RPMI 1640. 
Although, values for ADCC activity were generally lower in MEM 
supplemented with ATP. The inclusion of ATP or ascorbic acid, either 
alone or in combination, did not affect the inhibition of bovine 
neutrophil random migration by rboIFN-gamma (data not shown). Medium 
supplemented with tween 80 lowered the nontreated neutrophil values in 
both of the cytotoxic assays, without altering the neutrophil ADCC 
activity in the presence of rboIFN-gamma in either MEM or RPMI 1640. In 
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general/ the inclusion of these components (ATP/ ascorbic acid/ or tween 
80) had little affect on the cytotoxic activity of the bovine 
neutrophil. These commercially prepared media have also been evaluated 
for their ability to maintain human neutrophil function during long term 
incubation (Classer/ Piederlein/ and Huestis/ 1985). There were no 
apparent differences in the maintenance of neutrophil function in any of 
the media. 
Apparent media differences for the enhancement of bovine neutrophil 
AINC activity led to an investigation of the ability of huIFN-gamma in 
either M199 or MEM to enhance human neutrophil AINC activity. However/ 
the choice of medium did not make a difference/ human neutrophils 
apparently lack the ability to lyse CRBCs in RPMI 1640/ M199/ or MEM in 
the absence or presence of human gamma interferon (Figure 7). The 
enhancement of ADCC by the human neutrophils treated with huIFN-gamma 
was approximately the same in either RPMI 1640 or M199/ and was present 
although to a lesser extent in MEM (Figure 7). Random migration was 
similarly inhibited in all three media (Figure 8). These findings 
confirm previous reports and imply that in addition to granule component 
and surface receptor differences the neutrophils from these two species 
have target cell recognition or cytotoxic activity differences as well. 
In conclusion/ the ability of the bovine neutrophil to be activated 
by rboIFN-gamma to have enhanced antibody-independent cell-mediated 
cytotoxicity against ^^Cr-labeled CRBCs is apparently not a function 
shared by human neutrophils treated with huIFN-gamma. Interestingly, 
the amount of AINC activity against CROC targets by bovine neutrophils 
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dependent on assay conditions. Medium 199 was the optimal medium for 
expression of the AINC activity and, although lower, values in MEM were 
enhanced (P < 0.05). RPMI 1640, (a medium containing twice the Ca"*^, 
Mg"*"*", and glucose concentrations) did not support the bovine neutrophil 
AINC activity, and bovine neutrophil ADCC activities were more variable 
in this medium. RPMI 1640 does not lack any components that are 
contained in the other two media which support AINC activity. Three 
unique M199 components (ATP, ascorbic acid, and the fatty acid 
derivative, tween 80) known to have effects on neutrophil function and 
added to either MEM or RPMI 1640 were not instrumental in changing the 
AINC activity of bovine neutrophils in these media. It is quite possible 
that a more complete medium containing a mixture of these and other 
components, (in vivo conditions) is required before optimal activity can 
be attained. 
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SUMMARY AND DISCUSSION 
The first part of this study addressed the influence of recombinant 
bovine gamma interferon (rboIFN-gamma) on in vitro functions of bovine 
neutrophils. Neutrophils pretreated with rboIFN-gamma were found to have 
enhanced ability to lyse target cells in the presence (ADCC) and absence 
of target specific antibody (AINC). The enhanced ability of the 
neutrophil to act as an effector cell against virus-infected cells may be 
important in decreasing the incidence of bacterial pneumonia in bovine 
respiratory disease. Neutrophil random migration was inhibited by 
rboIFN-gamma treatment, while the other neutrophil functions (MPO-HgOg-
halide activity, ingestion, superoxide anion production) were not 
consistently affected. Inhibition of neutrophil random migration may be 
important in retaining the tissue neutrophils at the site of infection. 
The process of inhibiting random migration required both RNA and protein 
synthesis by the neutrophil. This was determined by the addition of 
inhibitors of these cellular processes during pretreatment and assay. 
Only brief exposure, five minutes, to rboIFN-gamma was required for the 
inhibition of neutrophil random migration. 
In order to better understand the activation process, the molecular 
events involved in the enhancement of neutrophil cytotoxicity were 
investigated in the second part of this study. The rboIFN-gamma treated 
and nontreated neutrophils were both capable of RNA and protein synthesis 
3 35 
as determined by the incorporation of H-uridine and S-methionine into 
acid precipitable macromolecules and by inhibitors of these cellular 
processes (alpha-amanitin, puromycin, cycloheximide). These events were 
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processes (alpha-amanitin/ puromycin, cycloheximide). These events were 
only required for the induction of AINC activity and were not required 
for the enhancement of ADCC by rboIFN-gamma. Recombinant boIFN-gamma-
treated neutrophils had enhanced expression of two major proteins, 
Mr=60/000 and 94,000 by SDS-polyacrylamide, linear-gradient gel 
electrophoresis. The kinetics of induction of these two proteins 
followed the time required for neutrophil activation and the expression 
of AINC activity. Both proteins were located in the neutrophil cytosol 
and were associated with the granule fractions. Neutrophils isolated 
from cattle immunosuppressed by intramuscular administration of 
glucocorticoids (dexamethasone) had depressed AINC and ADCC activities 
and enhanced random migration. Interestingly, rbolFN-gamma treatment 
(in vitro) did not enhance AINC, but reversed the suppression of ADCC 
and inhibited random migration to approximately normal levels. The 
protein synthesis patterns in the presence and absence of rboIFN-gamma 
were similar to those of neutrophils from nontreated cattle. It has 
been previously reported that arachidonic acid metabolism is suppressed 
in bovine neutrophils after in vivo administration of dexamethasone, 
specifically products of the 5-lipoxygenase pathway (leukotriene B^, 5-
HETE) were decreased (Webb and Roth, 1987). Inhibitors of arachidonic 
acid metabolism, nordihydroguaiaretic acid and BW755c, also inhibited 
the ability of rboIFN-gamma to induce neutrophil AINC activity, but did 
not affect enhancement of ADCC or inhibition of random migration. It 
appears that both the enhancement of AINC activity and inhibition of 
random migration by rboIFN-gamma require RNA and protein synthesis by 
151 
the neutrophil. The AINC activity is also dependent on the ability of 
the neutrophil to metabolize arachidonic acid. Whereas the enhancement 
of the ADCC activity by rboIFN-gamma did not require any of these 
cellular processes. 
The final part of this study evaluated the reported species 
difference in the ability of bovine and human neutrophils to express 
AINC activity after homologous gamma interferon treatment. Pretreatment 
and assay conditions utilized in previous human neutrophil studies 
(Basham/ Smith, and Merigan, 1984; Shalaby et al., 1985) and bovine 
neutrophil studies (Steinbeck, Roth, and Kaeberle, 1986) were 
reevaluated. The findings reaffirmed those of others, additionally we 
reported that human gamma interferon did not influence bovine neutrophil 
function. Since the medium conditions used on the neutrophils from both 
species differed, media normally used on human neutrophils (RPMI 1640, 
MEM) was tested on bovine neutrophils. Values for AINC activity were 
enhanced by rboIFN-gamma when neutrophils were incubated in MEM although 
to a lesser extent than in M199, but RPMI 1640 did not support this 
activity. Three components found in M199 were added to RPMI 1640 and 
MEM (both of these media are minimum essential media). These components 
(ATP, ascorbic acid, and tween 80), at higher concentrations, are known 
to have effects on other neutrophil and macrophage functions (Dallegri, 
Lanzi, and Patrone, 1980; Canning et al., 1985; Chiang, Kaeberle, and 
Roth, 1986). None of these components directly influenced the AINC 
results in either RPMI 1640 or MEM. Apparently no one component but the 
entire mixture of supplements are required for optimal AINC activity. 
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much as possible. The fact that there was a medium difference led us to 
reevaluate the ability of human neutrophils to express the AINC activity 
in all three media. The human neutrophils did not express enhanced AINC 
activity after homologous gamma interferon treatment in any of the media 
tested. Bovine and human neutrophils have differences in enzyme 
activities and surface receptor expression; the difference in induction 
of AINC activity by gamma interferon is another example of a species 
difference. 
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